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cis-Diamminedichloridoplatinum(II), or cisplatin (1), is a widely used platinum-
containing anticancer drug.
1
 Cisplatin is only effective against certain cancers, including 
testicular and ovarian cancer.
2 Although cisplatin in its mono- or bis-aquated form can 
coordinate to RNA, enzymes, and other sulfur-containing proteins, its anticancer activity 
is attributed to DNA binding.
3
 Despite its effectiveness against certain cancers, clinical 
usage of cisplatin is restricted by a number of dose-dependent side effects such as 
nephrotoxicity and neurotoxicity.
4
 Additionally, certain cancers showed intrinsic or 
developed resistance to cisplatin therapy.
5,6
 Over the past few decades, scientists have 
been trying to develop new platinum-based anticancer drugs that can overcome these 
problems. This chapter summarizes the mechanism of action, binding targets, and 













1.2 Cisplatin in cancer therapy 
1.2.1 Discovery of cisplatin 
Cisplatin (cis-diamminedichloridoplatinum(II)) is one of the most commonly used 
anticancer drugs in the world with a high success rate.
7
 The serendipitous discovery of 
the antitumor activity of cisplatin in the 1960s opened up a field of metallodrug 
development for cancer treatment. Dr. Barnett Rosenberg, a physicist at Michigan State 
University, was interested in studying the impact of electric currents on cellular division 
in bacteria.
8
 He carried out experiments using an apparatus with platinum electrodes 
immersed in ammonium chloride buffer, and he monitored Escherichia coli (E. coli) cell 
growth. After a period of time, E. coli cells were viewed under a microscope and found to 
have a long and filamentous shape instead of their normal length. This shape difference 
was found to be due to inhibition of cellular division.
8
 With further experiments, the 
compound that causes the inhibition was found to be a platinum(IV) complex with the 
formula [PtCl4(NH3)2] in its cis form.
9
 Because of the observed antiproliferative 
properties, it was of interest to test platinum compounds for their anticancer activity. 
Rosenberg and coworkers used the platinum(IV) complex cis-[PtCl4(NH3)2] and 
platinum(II) complex cis-[PtCl2(NH3)2] against Sarcoma 180 tumors in mice.
10
 The cis 
form of the platinum(II) complex cisplatin (cis-[PtCl2(NH3)2]) was found to be the active 
isomer; whereas, the trans complex was inactive (Figure 1.1). The treatment of tumors 
was a success, with mice showing no signs of cancer after 6 months.
10
 Following that 
result, cisplatin entered clinical trials and was approved for clinical usage in 1978.
11
 






Furthermore, cisplatin has been widely used to treat several other cancer types, including 




Figure 1.1. Structures of cisplatin (1) and transplatin (2). Both compounds have 
square planar geometry. 
 
1.2.2 The structural components of cisplatin 
The structure of cisplatin (1) (Figure 1.1) was first discovered by an Italian 
doctor, Michel Peyrone, in 1845.
12
 It has a square planar geometry with two chlorido 
ligands and two ammine ligands coordinated to the platinum metal center in the cis form. 
The transition metal platinum is in the +2 oxidation state, giving an overall charge of zero 
to the complex. Based on the mechanism of action, the chlorido ligands are displaced by 
water (aqua ligand) and the ammine ligands remain coordinated to the platinum center. 
Therefore, chlorido
 
ligands are referred to as the “leaving groups”, whereas the ammine 
ligands are referred to as the “carrier ligands” or “non-leaving groups.” As shown in 
Figure 1.1, two isomers exist, referred to as cisplatin (1) and transplatin (2).                                                      
1.2.3 Mechanism of action of cisplatin 
The anticancer activity of cisplatin is generally believed to be derived from its 
interactions with DNA.
12
 When cisplatin is administered intravenously, it encounters a 
relatively high Cl
-
 concentration (around 100 mM) in the blood. The higher Cl
- 
concentration (compared to cytoplasm) prevents displacement of the chlorido ligand on 1 




passive diffusion or via active transport using Cu-transporting proteins.
13,14
 Inside the 
cell, the Cl
-
 concentration is lower (4-20 mM) than outside, causing the cisplatin to 














Figure 1.2. Ligand exchange equilibria for cisplatin. The chlorido ligands of cisplatin 
are displaced by one or two aqua ligands to produce cationic mono- and diaqua 
complexes, respectively. The monoaqua complex readily coordinates to the N7 position 
of a guanine base in DNA. A bifunctional DNA adduct is formed after the second 




Monoaquation leads to generation of the charged reactive species of cisplatin 
(Figure 1.3, 3) and also prevents the molecule from diffusing out of the cell.
17
 
Electrostatic interactions favor attraction of the positively charged 3 to the negatively 
charged nucleic acid backbone. Upon interaction near a purine base, the aqua ligand is 
displaced from 3 and cross-linking to the nucleic acid occurs.
3
 After subsequent 
displacement of the second chlorido ligand by a neighboring purine base, a stable adduct 
is generated.
15
 Cisplatin preferentially coordinates to the N7 position of deoxyguanosine 
(dG) residues in DNA and makes 1,2-intrastrand d(GpG) adducts (Figure 1.3).
18
 The 




intrastrand d(GpXpG), in which X is an intervening deoxynucleotide, and interstrand 
adducts with DNA.
3
 The adduct formation distorts the DNA structure because of the 
structural constraints of the Pt atom. In particular, the 1,2-intrastrand adducts unwind and 
bend the DNA towards the major groove, exposing the minor groove.
1
 Proteins, such as 
those belonging to the high-mobility group (HMG) class, repair enzymes, and 
transcription factors, preferentially bind to the exposed shallow and wide minor groove 




Figure 1.3. A general pathway of cisplatin mechanism of action.
17
 Cisplatin (1) 
undergoes aquation and produces a positively charged species (3) inside the cell. 
Compound 3 coordinates to DNA and forms different adducts as shown. The adducts 
distort the DNA structure and initiate signaling cascades for cell death. 
 
There is evidence to suggest that cisplatin reacts with many other cellular 
components in the cell other than DNA.
17
 RNA, proteins, and other small molecules, 
particularly those that contain thiol groups such as glutathione, are some of the cellular 
targets of cisplatin (more details will be given in Sections 1.3 and 1.4.2). The nature of 




are not fully understood due to the complexity of the intracellular environment and the 
lack of methodologies to investigate these processes.
17
 Experiments are often carried out 
under in vitro conditions using activated cisplatin (aquated) and conditions that mimic the 
cellular environment to understand cisplatin accumulation on cellular components and 
how the resulting adducts affect normal cellular functions.
15
 
1.3 DNA as a target of cisplatin 
Numerous studies have focused on DNA as the main biological target of cisplatin 
that triggers the anticancer activity.
12
 There is extensive evidence that points to DNA as 
the primary target of cisplatin. Bacteria treated with cisplatin have shown phenotypic 
characteristics that are similar to the effects caused by DNA-damaging agents.
21
 
Moreover, DNA repair-deficient cells have shown more sensitivity towards cisplatin, 
strongly supporting DNA as the major cellular target.
22
 
Cisplatin enters the cell, undergoes mono- and/or bisaquation, and forms the 
activated species such as 3. These species need to cross into the nucleus in order to react 
with DNA. Once inside the nucleus, due to the high nucleotide concentration, aquated 
cisplatin readily reacts with DNA. Isolated and purified DNA from leukocytes of cancer 
patients following cisplatin treatment showed the presence of approximately 65% of 1,2-
d(GpG), 25% of 1,2-d(ApG), and 5-10% of 1,3-d(GpXpG) intrastrand cross-links.
19,23
 
Monofunctional adducts and interstrand adducts were also present in a smaller 
percentage. A significant structural effect on DNA was observed with the intrastrand 
adducts. The major 1,2-intrastrand cross-links unwind the DNA duplex and cause 
bending towards the major groove to generate a widened and shallow minor groove 
(Figure 1.4a).
24




quantified to be 32° using a gel electrophoresis mobility shift assay, and the angle for cis-
AG adducts is 34°.
24
 Another study reported bending of 33-35° and an unwinding angle 
of 15-20° in a DNA double helix.
25
 The interstrand cross-links also cause detrimental 
effects to the DNA structure by bending the helix towards the minor groove as shown in 
the X-ray crystal structure of a short DNA oligomer. (Figure 1.4c).
26
 Overall, cisplatin 
binding impacts the duplex DNA structure to a level that significantly affects replication, 
transcription, and repair.
17
 A variety of cellular proteins recognize and bind to the 
platinated DNA.
17
 Depending on the recognition selectivity and processing of the 
platinum adducts by cellular proteins, cytotoxicity of cisplatin would be mediated. 
 
Figure 1.4. Different adducts of cisplatin on double-stranded DNA. A cisplatin 1,2-
d(GpG) intrastrand cross-link on an 12-mer DNA (PDB ID: 1AIO) (a) is shown in 
comparison to a 1,3-d(GpTpG) intrastrand cross-link (PDB ID: 1DA4) (b), and an 
interstrand cross-link (PDB ID: 1A2E) (c). The DNA sequences (grey) for the 1,2-
d(GpG) and 1,3-d(GpTpG) intrastrand adducts are d(CCTCTGGTCTCC) and 
d(CTCTAGTGCTCAC), respectively, with their complementary sequences. The 
interstrand cross-link is shown at the DNA duplex with the sequence 
(CCTCG*CTCTC)d(GAGAG*CGAGG), where the adduct formation sites are indicated 
by asterisks. The C residues that are complementary to the Gs shown in asterisks are 
exposed to solvent in the crystal structure 1A2E. The cisplatin adduct is shown in red. 
 




Inhibition of DNA replication by cisplatin was discovered by using partially 
purified human DNA polymerase  and  with template DNA.
27
 Further experiments 
showed inhibition of activity of DNA polymerase I and III, as well as T4 DNA 
polymerase, caused by cisplatin adducts.
28
 Both DNA and RNA polymerases are strongly 
blocked by the bifunctional adducts compared to monofunctional adducts. Inhibition of 
transcription by cisplatin adducts was shown in in vitro studies using wheat germ RNA 
polymerase II, E. coli T7, and SP6 RNA polymerases.
29,30
 Since RNA polymerase II is an 
abundant protein in the cell and the main enzyme used to produce mRNA, it has been 
studied extensively with regard to cisplatin damage.
30
 In vitro experiments done using 
purified RNA polymerase II, transcription factors, and DNA templates have shown that 
the elongation is blocked by cisplatin 1,2-(GpG) and 1,3-(GpTpG) intrastrand cross-links 
(Figures 1.4a and 1.4b).
17
 In addition, RNA polymerase II stalling at the platination site 




In eukaryotes, DNA is associated with histone proteins and compacted into 
chromatin.
32
 Cisplatin has shown preferred binding to the open form of chromatin.
33
 
Cisplatin binding also blocks transcription factor binding and chromatin remodeling,
34
 as 
well as inducing phosphorylation and hyperacetylation in histone H3 and H4 proteins in 
HeLa cells, respectively.
35
 Furthermore, a recent structural analysis of a nucleosome 
containing a site-specific 1,3-(GXG) intrastrand adduct showed that the adduct changes 
the rotational setting of the DNA wrapped around the histone proteins.
36 
Cisplatin adducts on DNA can be removed by different repair pathways. The 






 Transcription-coupled repair (TCR) and global genomic repair (GGR) 
are the two key initial mechanisms of NER (Figure 1.5). Xeroderma pigmentosum 
proteins (XPA, XPB, XPC, XPD, XPF, XPE, and XPG) are involved in these 
mechanisms. As mentioned earlier, the signal to initiate TCR is RNA polymerase II 
stalling at the platination site and interactions with cockayne syndrome proteins, CSA 
and CSB.
37
 For GGR, XPC-HR23B is the damage recognition protein.
17
 After the initial 
recognition, both TCR and GGR follow the same path to repair the DNA. First, proteins 
XPA, replication protein A (RPA), and transcription factor TFIIH assemble on the DNA 
in a cooperative fashion.
17
 XPB and XPD helicases, which are components of TFIIH, are 
responsible for DNA unwinding, and XPG binds to the unwound DNA. This step is 
followed by XPF-ERCC1 binding and removal of oligonucleotides containing the 
platinum adducts by a dual incision. RPA then recruits DNA resynthesis factors to fill the 
gap. This pathway of DNA repair has been well studied, and supported by the fact that 
Xeroderma pigmentosum cell lines lacking components of NER are more sensitive to 
cisplatin than normal cells.
38
  
Overall, the significant effect and outcomes of cisplatin binding to DNA on 
replication, transcription, and repair processes are evidence to confirm that DNA is a 
major target of cisplatin. However, there are still many problems associated with the 






Figure 1.5. Nucleotide excision repair pathway for removing cisplatin lesions. The 
proteins involved in the transcription-coupled repair pathway or global genome repair 
pathway initially recognize the Pt lesion (red), which is then removed by the NER 
pathway. The Pt adduct is removed along with a flanking DNA region that is 24 to 32 
nucleotides in length. 
 
1.4 RNA as a target of cisplatin 
The idea of cisplatin binding to DNA as the main driver for cancer cell apoptosis 
has been challenged by a variety of studies that show cisplatin binding to RNA, proteins, 
peptides, and lipids.
39-41
 These studies point to cisplatin toxicity originating from multiple 
sources rather than solely from binding to DNA. Among these, RNA is a poorly 
characterized target considering its important regulatory roles in the cell. Particularly 
considering cisplatin coordination modes with purine bases, RNA could also be a target, 
possibly leading to some of the toxicity caused by the drug. Various regulatory roles of 




Experiments have been done to characterize cisplatin binding sites on RNA and 
determine rates of reactions with RNA compared to DNA. For example, cisplatin binding 
sites in ribosomal RNA hairpins were analyzed using radioactive labeling and enzymatic 
footprinting.
42,43
 The binding preference of cisplatin for certain RNA secondary 
structures was analyzed by the Elmroth group using full-length tRNA
Ala
 and hairpin 
models of its acceptor stem and anticodon loop, and the results showed that platinum 
coordination to RNA is highly sequence and structure dependent.
44,45
 In a recent report by 
the DeRose lab, RNA-Pt adducts in cisplatin-treated Saccharomyces cerevisiae were 
quantified by using inductively coupled plasma mass spectrometry (ICP-MS).
46
 These 
results suggested that cisplatin accumulates faster and is retained more on RNA 
compared to DNA. These studies also showed that cisplatin could interfere with several 
enzymatic activities, including exonuclease, endonuclease, and reverse transcriptase, 
even with a single adduct on the RNA strand. A number of studies focused on evaluating 
the reaction kinetics of cisplatin on DNA and RNA.
47-50
 In one of those studies, cisplatin 
and its derivatives were reacted with RNA and DNA hairpins of similar sequence, 
namely r(CGCGUUGUUCGCG) and d(CGCGTTGTTCGCG), and found to have higher 
platination rates with the RNA hairpin.
51
 
Very few crystal structures of platinum compounds bound RNA were available up 
to 2016. A low-resolution structure of yeast tRNA
Phe
 showed two major cisplatin binding 
sites.
52
 The first nearly atomic resolution crystal structure of cisplatin bound to the 
Thermus thermophilus 70S ribosome was reported in 2016.
40
 This 2.6 Å-resolution X-ray 
structure reported nine cisplatin binding sites on the ribosome out of 2200 potential 




subunit, six were on the 50S large subunit, and one was bound to the L9 ribosomal 
protein. When comparing the cisplatin coordination sites, three were located at the N7 
position of adenosine nucleotides (A790 of 16S rRNA; A1848 and A2531 of the 23S 
rRNA), and five were at the N7 atoms of guanosines (G1300 of 16S rRNA; and G27, 
G425, G1606, and G2220-2221 of 23S rRNA). These crystal structure data shed light on 
our understanding of the RNA-cisplatin interactions and patterns, such as base preference 
and site of modification. 
 
 
Figure 1.6. The crystal structure of Thermus thermophilus ribosomal subunits with 
cisplatin binding sites (PDB ID: 5J4B).
40
 (a) The 50S subunit is shown with six 
cisplatin adducts (red) on 23S rRNA (grey) and one adduct on the L9 ribosomal protein 
(green). (b) The 30S subunit has two cisplatin binding sites. Examples of cisplatin 
binding at different residues, namely (c) G26, (d) A2531, and (e) Met1 of the L9 protein 








The previous work mentioned above led to the hypothesis that RNA-related 
processes may be inhibited by cisplatin and its derivatives. An earlier study done with 
platinated messenger RNA showed inhibition of in vitro translation activity.
53
 
Concentration and time-dependent inhibition of peptide synthesis were observed by 
cisplatin in this study, and maximum inhibition was detected after 30 min drug exposure. 
Furthermore, inhibition of peptide synthesis was observed at cisplatin concentrations as 
low as 3 M. Another study showed that cisplatin is capable of making cross-links in 
structurally complex RNAs such as the internal loop region of spliceosomal RNAs.
54
 
Moreover, a cisplatin derivative was used to introduce a site-specific cross-link within the 
active site of a hammerhead ribozyme.
55
 These studies showed that platinum compounds 
have the ability to introduce distance constraints for dynamic and complex RNA 
structures, therefore impacting the RNA function. Another study revealed inhibition of 
telomerase activity caused by cisplatin binding in human testicular cancer cells.
56
 
Telomerase is a ribonucleoprotein that adds TTAGGG tandem repeat sequences to 
telomeres using the RNA component of the enzyme. The telomere, the RNA component 
of the telomerase enzyme, and the gene encoding the RNA component all contain G-rich 
sequences; therefore, cisplatin is capable of making cross-links and inhibiting the 
telomerase activity through multiple mechanisms. Reduced telomerase activity is 
observed in a concentration-dependent manner by cisplatin; whereas, there weren’t any 




As discussed above, cisplatin and platinum(II) compounds have been studied in 




including the impact on mRNA, tRNA, rRNA, spliceosomal, and telomeric RNA 
function. However, the underlying mechanism of RNA recognition by cisplatin and 
thereby the inactivation of RNA is still not fully understood. Considering the fact that 
cisplatin and its derivatives are capable of inactivating a number of essential RNA-related 
functions, determining the link between RNA and cisplatin toxicity seems worthwhile.  
1.5 Drawbacks associated with platinum-based anticancer drugs 
Despite its significant success, cisplatin is not a perfect anticancer drug. The side 
effects caused by cisplatin are a significant limitation.
57
 Common side effects include 
nausea, vomiting, diarrhea, temporary hair loss, signs of dehydration, neurotoxicity, 
nephrotoxicity, and ototoxicity.
57
 The severe side effects of cisplatin result in part from 
its inability to distinguish tumor cells from normal cells. Therefore, a major concern for 
next-generation anticancer drug development is achieving selectivity for tumors over 
normal cells in humans. 
On another note, cisplatin is successful for treatment of only certain cancers, and 
is therefore not universally employed for all cancers. For example, cisplatin cures 
testicular cancer with a rate of 90%, and nearly 100% if the cancer is found in the early 
stages.
17
 With ovarian cancer, there is an initial cure rate of up to 70% with cisplatin; 
however, the five-year patient survival rate is about 15-20%.
58
 With small cell lung 
cancer, the relapse rate could be as high as 95%.
58
 This relapse occurs as cancer cells 
develop resistance to cisplatin therapy over time.
59
 Some cancers could be intrinsically 
resistant to cisplatin and other platinum-based drugs, whereas others acquire resistance 
over time.
59
 The cross-resistance of tumors to diverse antitumor drugs suggests that they 
could share common mechanisms of resistance.
58




these resistance mechanisms to refine therapeutic approaches to battle cancer. Figure 1.7 
summarizes the major pathways that cancer cells could use to develop resistance towards 
cisplatin and other platinum drugs. Such resistance mechanisms arise as a result of 
intracellular changes that prevent cisplatin from binding to DNA, activating the apoptotic 
signal pathway, or both. These pathways include changing the amount of cisplatin uptake 
and efflux, detoxification of the drug, platinum adduct repair in the cell, and inhibition of 
apoptosis. These mechanisms are discussed below in detail. 
 
Figure 1.7. Cisplatin resistance mechanisms.
60
 The level of cisplatin in the cell and 
how the cell responds to the drug in the cytoplasm and nucleus determine the anticancer 
activity of cisplatin. 
 
1.5.1 Decreased uptake and increased efflux 
The level of drug accumulation inside the cell determines the anticancer activity 
of the molecule. Drug accumulation changes as a result of reduced drug uptake, increased 
efflux, or both.
58
 Tumor cells that are resistant to cisplatin have shown a higher 






 Cells overexpressing the MRP2 gene have demonstrated a 10-fold higher 
resistance to cisplatin than cells with normal levels of MRP2.
61
 Cells overexpressing 
ATP7B, a copper-transporting P-type ATPase protein, demonstrated a 9-fold greater 
resistance to cisplatin due to higher efflux.
62
 Some studies also showed that cells with 
increased levels of p-glycoprotein or the major vault/lung resistance-related protein 
(MVP/LRP) also have poor outcomes towards cisplatin therapy.
58
 However, further work 
is required to confirm the role of these proteins in cisplatin resistance.  
1.5.2 Detoxification by thiol-containing molecules 
 After activation in the cell, the aquated form of cisplatin is very reactive towards 
cellular components, particularly the abundant glutathione (GSH) and cysteine-rich 
metallothioneins.
58
 Based on the hard-soft acid-base (HSAB) principle, Pt(II) is a 





of cisplatin with cellular thiol-containing molecules decreases the level of available 
complex to react with DNA, therefore promoting cisplatin resistance. This correlation 
between increasing levels of GSH and resistance was confirmed with a panel of resistant 
ovarian tumor models and in clinical studies.
64,65
 Metallothioneins also have S-containing 
reactive centers that participate in cisplatin coordination; therefore, it is not surprising to 
see elevated metallothionein levels in cisplatin-resistant tumor cells.
66
 Increased GSH 
expression level is a result of increased expression of the γ-glutamylcysteine synthetase 
(γ-GCS) gene, which is an important enzyme for GSH biogenesis.
67
 Higher expression of 
GSH and metallothionine following cisplatin treatment could result from their 







1.5.3 Increase in DNA damage repair 
Cisplatin-induced DNA damage repair is explained in the Section 1.2. NER is the 
main mechanism used to remove the platinum adducts from DNA. Since DNA adduct 
formation is believed to be the lead mechanism for anticancer activity of cisplatin, 
removal of these adducts could be another pathway to acquire resistance. ERCC1 is one 
of the core proteins associated with the NER pathway, and up regulation of this protein is 
associated with cisplatin-based resistance due to increased DNA damage repair.
69
 DNA 
mismatch repair (MMR) is another pathway for DNA damage repair in cells.
70
 The down 
regulation or mutations in the MMR genes and the proteins (MutSα and MutSβ) in the 
MMR pathway are associated with cisplatin resistance.
71
 Base excision repair (BER) has 
been proposed to play a role in cisplatin resistance in cells as well.
72
 Low-fidelity DNA 
polymerase β, which is a part of the BER machinery, is capable of bypassing cisplatin 
intrastrand adducts, which might lead to cisplatin DNA-damage tolerance.
70
 Overall, 
increased removal of cisplatin adducts in the NER pathway, reduced cytotoxicity due to 
poor recognition of the adducts, and bypassing cisplatin intrastrand adducts in the MMR 
and the BER pathways lead to cisplatin resistance in cancer cells. To overcome the 
cisplatin-associated resistance, new drugs need to be developed with different anticancer 
mechanisms.  
1.6 Other platinum-based anticancer compounds 
 Since its introduction as a cancer therapeutic, cisplatin has made a major impact 
in cancer medicine as a successful drug and also as a model for platinum-based 
anticancer drug development.
7
 Unfortunately, cisplatin is not universally effective on 




the need for new drug development. The general structural features of the platinum 
compounds are shown in Figure 1.8.
73
 Varying ligands contribute to the anticancer 
properties of the drug differently; therefore, it is important to understand these features to 
strategically modify or synthesize novel compounds. The non-leaving group, L, has the 
ability to interact with DNA and is usually a nitrogen donor. This group will determine 
the nature of the Pt adduct, structural impacts, and the resistance profile. The leaving 
group, X, will be removed upon aquation and governs the aquation kinetics and toxicity 
profiles. Typically, platinum(II)-based drugs have two L groups and two X groups in the 
cis configuration. By strategically modifying the ligands, the lipophilicity and solubility 
of the complex can be altered. Platinum(IV) complexes have additional axial ligands (R 
groups) that govern cell targeting, lipophilicity, and solubility.  
Figure 1.8. Different components of classical platinum anticancer drugs. The 
properties determine by each group are listed. Platinum(II) drugs have two X and two L 
groups in the cis configuration. Platinum(IV) compounds have two additional groups, R. 
 
1.6.1 Clinically available platinum drugs 
 Out of more than thousands of molecules that have been synthesized and tested 




with cisplatin. They are carboplatin and oxaliplatin (Figure 1.9).
73
 Nedaplatin, lobaplatin, 
and heptaplatin are approved for regional use in Asia (Figure 1.9).
73
 Overall, these 
molecules bind to DNA and have a similar mechanism of action as cisplatin leading to 
apoptosis. However, differences in the non-leaving group ligands result in different DNA 
adduct profiles, and therefore could be repaired at different rates.  
The success of cisplatin led to a systematic development of new platinum-based 
drugs. Carboplatin is one such outcome that was approved for medical use in 1989.
74
 It is 
widely used to treat ovarian cancers, but has also been used for brain, breast, testes, 
cervix, and lung cancers. It has a relatively stable 1,1-cyclobutanedicarboxylato 
(CBDCA) ligand as its leaving group that has a lower aquation rate (rate-determining 
step in the mechanism) and lower toxicity than cisplatin.
75
 It therefore has lower reaction 
kinetics with cellular components compared to cisplatin, thus limiting off-target effects. 
Because of these reasons, higher doses of carboplatin can be administered.
76
 On the other 
hand, it has the same ammine groups as non-leaving group ligands; therefore, carboplatin 
has a similar mechanism of action and resistance profile as cisplatin.
75
  
Figure 1.9. Structures of clinically approved platinum(II) drugs. Carboplatin and 
oxaliplatin are second-generation Pt(II) drugs, and nedaplatin, heptaplatin, and lobaplatin 






































Oxaliplatin gained approval for international marketing in 1996 for combination 
chemotherapy for colon cancer.
77
 It has an oxalate leaving group and R,R-
diamminocyclohexane (DACH) non-leaving group ligand. Experimental data revealed 
that oxaliplatin utilizes organic cation transporters (OCT) for cell penetration, and the 
overexpression of OCTs in colon cancer provides a rationale for effectiveness of this 
drug against colon cancer.
77
 
Nedaplatin was developed in Japan and approved for clinical use in 1995.
78
 The 
glycolate leaving group confers higher water solubility to the molecule compared to 
cisplatin. Nedaplatin has the same non-leaving ammine ligands as cisplatin and 
carboplatin. It is primarily used to treat esophagus, head and neck, small cell lung 
cancers, and non-small cell lung cancers.
79
  
Heptaplatin and lobaplatin are third-generation cancer drugs. Hepataplatin was 
developed in Korea to treat gastric cancer.
7
 As shown in Figure 1.9, it has a malonate 
leaving group and 2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanammine as the non-
leaving group ligand, which forms a seven-membered chelate ring.
80
 
Lobaplatin was initially developed in Germany, but only has regulatory approval 
for clinical use in China.
7
 Initially it was used to treat chronic myelogenous leukemia, but 
is now used to also treat small cell lung cancers and metastatic breast cancer.
7
 Lobaplatin 
is a heptaplatin derivative, but with different L and X ligands. 
1.6.2 Other Pt(II) complexes 
 A large number of platinum(II) complexes has been developed and tested for their 
anticancer activity in both academia and industry. Conjugation of biologically available 




and achieving selectivity of platinum-based drugs. For example, glycoconjugation has 
been introduced to selectively target cancer cells with higher glucose transporter 
expression. Furthermore, these compounds have increased water solubility and reduced 
toxicity. There are a variety of platinum-containing molecules with sugar groups attached 
as non-leaving groups or leaving groups that are analogous to cisplatin and oxaliplatin 
(Figure 1.10).
81-83
 Primarily, the work in this area has been limited to synthesis of the 
complexes and testing for cytotoxicity. The first Pt(II) complex with an attached amino 
sugar is shown in Figure 1.10a.
84
 Recently, some effort has been made to establish a link 
between platinum-sugar conjugation and uptake using specific receptors in cancer cells.
83
 
The first experimental evidence of sugar-linked oxaliplatin analogs exploiting the glucose 




Figure 1.10. Structures of carbohydrate-linked Pt(II) complexes. (a) PtCl2(methyl 
2,3-diammino-2,3-dideoxy-α-D-mannopyranoside
84
 and (b) cis-dichlorido[(2-β-D-
glucopyranosidyl)propane-1,3-diammine]platinum(II)
82
 are cisplatin derivatives with 
sugar groups attached as non-leaving group ligands. (c) (trans-R,R-cyclohexane-1,2-
diammine)-malonatoplatinum(II)
81
 and (d) glucose-Pt(II) complex
83
 are oxaliplatin 
derivatives, in which sugar groups are attached to the leaving group. 
 























































group (estrogen and testosterone) attached as the non-leaving group ligand (Figure 
1.11).
85
 Steroids have been used as targeting groups that utilize the overexpressed steroid 
receptors on certain cancer cells. For example, estrogen receptor is overexpressed in 
breast cancers to stimulate proliferation.
86
 The rationale for attaching steroids is that they 
can kill the cancer cells by either enhanced uptake of the platinum drug or by blocking 
the steroid receptor from its biological function.  
 
Figure 1.11. Structures of estrogen receptor ligands attached to Pt(II) complexes.  
(a) cis-dichlorido[N-(4-(17α-ethynylestradiolyl)-benzyl)-ethylenediammine]platinum(II) and 
(b) cis-diammino[2-(4-(17α-ethynylestradiolyl)-benzoylamino)-malonato] platinum(II) 





Conjugating amino acids or peptides to make platinum(II) complexes is another 
idea that has been explored (Figure 1.12). Earlier studies showed that conjugation of 
netropsin and distamycin peptides, which are minor groove DNA binders, change the 
overall complex binding preference to poly(dA) over poly(dG).
87
 Altered specificity for 
A residues on RNA was also observed for some amino-acid-linked cisplatin analogs with 
























Figure 1.12. Structures of Pt(II) complexes attached to amino acids and peptides. (a) 





In hopes of altering the spectrum of activity and thereby circumventing the 
drawbacks associated with clinically available drugs, researchers are introducing large 
changes to the general structure of platinum(II) compounds as shown in Figure 1.12. 
Another expectation of this search for new ligands is to find platinum drugs that are 







 are some of the non-classical compounds being 
explored.  
1.6.3 Platinum(IV) complexes 
 Platinum(IV) complexes have octahedral geometries, which differs from the 
square planar platinum(II) complexes. The two extra ligands in the complex can be used 
to tune cellular targeting, lipophilicity, uptake, and delivery.
7
 Although the platinum(IV) 














































significance was only recognized recently.
93
 Platinum(IV) complexes are more resistant 
to ligand substitution than the platinum(II) complexes; therefore, they can be used as 
prodrugs to minimize unwanted side reactions before reaching target DNA. When 
reacting, Pt(IV) will undergo reduction to yield Pt(II) reactive species. Some of the 
Pt(IV) drugs that have reached clinical trials are tetraplatin, satraplatin, and iproplatin 
(Figure 1.13).
7
 Out of these, satraplatin is the first orally active platinum complex to be 
synthesized.  
 
Figure 1.13. Chemical structures of Pt(IV) complexes. Structures of tetraplatin, 
iproplatin, and satraplatin are shown. 
 
1.7 Platinum complexes as chemical probes 
 Cisplatin and a large number of platinum compounds have been synthesized and 
tested for their anticancer activity over the years.
7
 The possibility of attaching different 
ligands to the platinum center as discussed in the above sections could be utilized to 
introduce new functionalities to the drug. While these modifications are introduced to 
improve the anticancer properties of the drug, there are some instances in which the 
modifications introduce other properties to the complex that allow for example 
visualization and purification.
94
 Such properties allow the derivatives to be used as 
probes in biochemical studies. In this section, a new role of platinum complexes as 




























 A chemical probe is a small molecule that interacts with specific targets to 
provide information about that target. The reaction could also provide information about 
the environment, in which the target resides. Cisplatin forms stable and inert bonds with 
purine residues, allowing the adducts to be analyzed using a variety of techniques. For 
example at the nucleoside level, adducts can be detected and analyzed using high 
performance liquid chromatography (HPLC) and mass spectrometry (LC-MS).
95
 In the 
context of nucleic acids, the adducts can be analyzed using gel electrophoresis techniques 
as well.
95
 Cisplatin is a small molecule with a +1/+2 charge depending on aquation. As 
mentioned earlier, cisplatin’s size, charge, and reactivity can be altered by changing the 
non-leaving group ligands. For example, fluorophores have been attached to detect the 
drug localization within complex cellular environments.
94,96
 Furthermore, attachment of a 
reactive handle such as a “clickable” group to the Pt complex provides ways to 
incorporate a variety of functional groups (Figure 1.14).
94
 This approach could be used 
for detection, isolation, and purification of Pt-bound targets.  
 
Figure 1.14. Chemical structures for cisplatin derivatives with “clickable” groups.
94
 
The (a) azide-appended and (b) alkyne-appended complexes can undergo click 
modification with another molecule with the counter-reactive part. 
 
 The information gained from cisplatin binding sites reflects how other small 
molecules find their targets, and could be used for novel drug development. Cisplatin can 



























Additionally, cisplatin reactivity can be quenched using high chloride concentrations, 
which allows it to be used for monitoring binding kinetics. Differences in platination 
rates upon changes in the reaction medium (for example, salt, pH, and the presence of 




 For the purpose of this thesis work, we were particularly interested in exploring 
cisplatin and its derivatives as probes for RNA structure. RNA plays important regulatory 
roles in the life cycle of a cell by modulating gene expression. Therefore, RNA has 
received much attention by scientists as a promising target for drug development. As the 
protein synthesis machinery in the cell, the ribosome has been a validated target for both 
anticancer and antibacterial drugs, and still has great potential for further exploration.
97
 In 
order to find possible target sites, selective chemical reagents are needed to probe the 
structural details of rRNA in vivo and in vitro.
98
 Figure 1.15 shows some of the chemical 
probes that are available for RNA structure studies. Chemical probing techniques are 
useful in studying RNA structure at near physiological solution conditions and reveal 
information at the nucleotide level.
99
 Compared to some other structure probing methods 
such as NMR spectroscopy and X-ray crystallography, only small amounts of sample 
(pmoles) are needed for chemical probing.
99,100
 One limitation of this method is that only 





 Additionally, these reagents are reactive at specific sites; 
therefore, they cannot detect some of the desired sites or need additional steps for 




modification by DMS, aniline treatment has to be done, as methylation at this site doesn’t 
directly inhibit reverse transcription.
101
 
 The use of cisplatin as a chemical probe for RNA has been reported previously by 
our lab previously.
43
 By changing the non-leaving ligand to amino acids, the reactivity of 
the platinum complex has been altered, and this method has provided information about 
accessibility of rRNA towards various ligands.
88
 Moreover, cisplatin has been used for 
both in vitro and in vivo probing, and adducts are identified by reverse transcription stops. 
Studies from our lab have also shown the feasibility of using cisplatin kinetics to 




Figure 1.15. The chemical probes and their target sites. Certain modifications (e.g., 
methylation or alkylation at N1-A, N3-C, N1-G, and N3-U) are detected by reverse 
transcription (RT) analysis. Modifications at the N7-G position by DMS are detected by 



















































































1.8 Aminoglycosides: RNA targeting antibiotics 
Aminoglycosides are small molecule, broad-spectrum antibiotics that target 
bacterial ribosome and inhibit translation.
102
 Commonly, aminoglycosides are composed 
of a 2-deoxystreptoamine (2-DOS) subunit that is connected to different amino sugar 
rings via glycosidic linkages (Figure 1.16). Streptomycin is an example of an 




Figure 1.16. Chemical structures of aminoglycosides. Neomycin, paromomycin, 






Aminoglycosides inhibit protein synthesis by binding to the A site (helix 44, or 
h44) of the 16S ribosomal RNA with a moderate (μM) affinity.
103
 Binding of the 
aminoglycosides induces or stabilizes an extrahelical conformation of residues A1492 
and A1493.
104,105
 These residues are important for aminoacyl tRNA recognition and 
mRNA translocation.
106,107
 Aminoglycoside binding stabilizes the h44-mRNA-tRNA 
complex and induces codon misreading, translocation abortion, and decreased translation 
fidelity.
108,109
 Crystal structures have also shown a secondary binding site for neomycin, 
paromomycin, and gentamycin at helix 69 (H69) of 23S rRNA as well.
106,110,111
 The 




With the emergence of the antibiotic resistance, it is important to understand the 
underlying principles of drug-target interactions in order to develop novel drugs. 
Chemical tools are necessary to understand the electrostatics and salt-dependent 
properties in aminoglycoside-nucleic acid interactions. Chapter 6 of this thesis describes 
the feasibility of using cisplatin kinetics to investigate these RNA-drug interactions. 
1.9 Thesis overview and specific aims of the research  
Serendipitous discovery of cisplatin opened up a field of metallodrug 
development for cancer treatment.
8
 Strategic development of platinum and other metal-
containing drugs has led to successful approval of treatments for several cancer types. 
Notably, platinum-containing drugs such as carboplatin and oxaliplatin, which were 
developed based on cisplatin, are prevailing in the treatment of cancer.
113,114
 However, 
new platinum-based anticancer agents are only slowly being introduced to the clinic. 




can be explored to develop next-generation platinum drugs that overcome the drawbacks 
associated with the parent drugs. In recent years, synthesis of platinum(II) complexes 











 have been explored because of their reduced 
toxicity. Among these, glycoconjugation has received much attention. Carbohydrates are 
important elements in many drugs that target DNA and RNA.
119,120
 There is recent 
evidence to suggest that carbohydrate motifs are utilizing glucose transporters for 
targeted delivery to cancer cells.
83,121
 Despite the fact that glycoconjugation reduces 
overall toxicity of platinum drugs, leads to higher potency,
82
 and facilitates targeted 
delivery
83
, the impact of the sugar motif on the mechanism of cell death is still largely 
unknown. The ability of carbohydrates to form a number of hydrogen-bonding 
interactions and presence of the larger sugar group within the Pt coordination sphere can 
influence the reactivity of these molecules. To gain insight into the behavior of 
glycoconjugated platinum(II) complexes compared to cisplatin, I utilized a cisplatin 




Figure 1.17. The structure of sugar-conjugated cisplatin derivative, compound 5. 
The cisplatin derivative cis-dichlorido[(2--D-glucopyranosidyl)propane-1,3-
diammine]platinum(II) is shown. 
 
 I also carried out experiments to reveal the feasibility of using cisplatin as a probe 

















moderate affinity and poor selectivity. In order to develop new antibiotics, it is of 
importance to understand the structural mechanisms used by aminoglycosides to target 
RNA. It is challenging to experimentally determine the electrostatic environments that 
are involved in drug-RNA interactions; however, certain studies have shown the 
importance of the high number of positive charges on aminoglycosides in binding to 
RNA.
122,123
 Isothermal titration calorimetric studies of neomycin B binding to a RNA 
stem loop revealed the contribution of hydrogen-bonding and electrostatic contacts.
122
 
Salt-dependent variations in binding were attributed to electrostatic contacts. However, 
there is still a lack of information on the relative contributions of electrostatic interactions 
for aminoglycoside binding and techniques to evaluate the electrostatic interactions. 
Experiments were carried out to achieve these goals with the following specific aims. 
Aim 1: Determine the reactivity preferences, reaction rates, and the products 
formed for the reaction between compound 5 and nucleosides 
 Many known platinum(II) complexes prefer binding to the guanine base, but there 
are exceptions to this observation. For example, changing the non-leaving group ligand to 
amino acids such as ornithine and lysine has been shown to alter the binding preference 
to adenine.
88
 The first aim of this thesis work was to determine the binding preferences of 
a carbohydrate-linked cisplatin analog (5) in the context of nucleosides. HPLC and LC-







Aim 2: Investigate the reaction rates, binding sites, and structural impacts of 
compound 5 at the oligonucleotide level 
Reactivity at the nucleoside level does not reflect influences of the nucleic acid 
backbone. Therefore, it is important to analyze drug reactivity at biologically relevant 
conditions to fully understand activity within the context of a cell. In this thesis work, 
kinetic experiments were carried out to determine the reaction rates and characterize 
DNA and RNA oligomers. Gel-based assays were used for the rate determination with 
mono- and bisactivated compound 5 in comparison to cisplatin. Additionally, reaction 
rates were obtained in the presence of varying salt conditions to understand the effect of 
electrostatics and the role of the sugar moiety on the overall binding kinetics. Moreover, 
the structural effects of binding were also evaluated using different gel-based assays in 
the context of plasmid DNA and DNA oligomer.   
Cisplatin anticancer activity is mainly associated with DNA binding. However, 
with more mechanistic studies being done, this idea has been challenged and cisplatin 
was shown to bind to other cellular targets such as RNA and proteins, which could also 
disrupt cellular functions and lead to cell death.
39,53,56
 In particular, cellular RNA has 
received increased attention in recent years.
40,46,124
 My hypothesis was that an attached 
sugar group and overall positive charge would facilitate compound 5 accumulation on 
RNA. The chemical probing technique was used to detect reactive sites on the 






Aim 3: Evaluate the cytotoxicity of compound 5 against cancer cell lines compared 
to normal cells and quantify its accumulation levels 
 To explore the cytotoxicity of 5 towards various cancer cell lines, a series of MTT 
(3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium bromide) assays were carried out 
in this thesis work. Comparable cytotoxicity of compound 5 with cisplatin had previously 
been reported for ovarian and melanoma cancer cell lines, but my goal was to expand this 
study to other cancer cell lines (e.g., prostate) as well as the corresponding normal cell 
lines. My hypothesis was that selective cancer cell targeting could be achieved by 
utilizing a characteristic feature of certain cancer cells, specifically enhanced uptake of 
glucose.
125
 This idea was previously explored with glycoconjugated oxaliplatin 
derivatives, but not with cisplatin derivatives such as compound 5.
83
 Therefore, it was of 
interest to explore the differential accumulation of compound 5 in cancer cells compared 
to normal cells. As a proof of concept, the DU145 prostate cancer cell line was selected 
for this comparison based on the higher glucose transporter expression levels,
126
 along 
with the normal prostate cell line-RWPE1.
83
 
Aim 4: Probe RNA-aminoglycoside interactions using cisplatin kinetics as a tool 
 Based on a previous study from our lab that showed salt-dependent cisplatin 
coordination rates to RNA, we postulated that positively charged aminoglycosides could 
also impact the platination rates by competing with cisplatin for the target. Herein, I 
describe a kinetic method to monitor aminoglycoside interactions with RNA using 
cisplatin coordination rates. A gel-based assay was used to obtain the cisplatin 







BIOCHEMICAL METHODS, CELL STUDIES, AND DATA ANALYSIS 
2.1 Abstract 
 The work discussed in this thesis largely focuses on understanding the underlying 
mechanisms of platinum(II) complex activity and using certain features of these  
anticancer drugs for chemical probing. A variety of biochemical, bio-analytical, and 
molecular biology techniques were utilized for these purposes. Gel-based techniques 
were used to analyze product formation with DNA and RNA to observe, nucleic acid 
structural changes, and to obtain kinetic parameters for reactions between a carbohydrate-
linked Pt(II) complex (5) and the parent compound cisplatin. These methods include 
agarose gel electrophoresis, as well as native and denaturing polyacrylamide gel 
electrophoresis (PAGE). Radioactive labeling was employed for visualization of the 
nucleic acids in the gels. In addition, high performance liquid chromatography (HPLC) 
and mass spectrometry (MS) techniques such as matrix-assisted laser desorption 
ionization (MALDI) and liquid chromatography mass spectrometry (LC-MS) were used 
for product characterization (e.g., identity and quantity). Another goal of my thesis work 
was to understand the cellular toxicity and accumulation of the carbohydrate-linked Pt(II) 
compound (5) compared to the already known anticancer drug cisplatin. Cellular toxicity 
was assessed using an MTT (3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay, and Pt levels in the cell were determined by using inductively coupled 
plasma mass spectrometry (ICP-MS). The methods describe in this chapter were utilized 
to examine Pt-RNA or Pt-DNA interactions, but could also be employed with other small 





2.2.1 Reactivity and Pt(II) coordination rates with nucleosides and oligonucleotides 
 To evaluate the binding preferences of compound 5 with different RNA 
nucleosides (Figure 2.1), the reactions were analyzed by reverse-phase HPLC on a C18 
column. Depending on the observed product formation, only certain nucleosides such as 
guanosine were selected for kinetic experiments. The rates of Pt(II) complex coordination 
to guanosine (G) and deoxyguanosine (dG) were determined by using HPLC-based 
assays as described in Section 2.4.4. The products were characterized by LC-MS. 
Figure 2.1. The chemical structures of RNA and DNA nucleosides. Adenosine, 
deoxyadenosine, guanosine, and deoxyguanosine have purine bases, whereas cytidine, 
deoxycytidine, uridine, and thymidine have pyrimidine bases.  
 
Experiments were carried out to compare the reactivity of Pt(II) complexes at the 
oligonucleotide level (Section 2.4.9). Based on the reactivity at guanine bases, nucleic 
acid sequences with guanosine residues were employed. To determine the platination rate 
constants, an electrophoretic mobility shift assay (EMSA) technique was employed. The 
kinetic experiments were carried out using mono- or bis-activated Pt(II) compounds for 
comparison. Rates were obtained under different buffer conditions for the reactions 
between DNA/RNA and mono-activated Pt(II) compounds. All of the experiments were 




For all of the kinetic experiments carried out in this thesis work, pseudo-first-
order conditions were maintained.
51
 More specifically, the concentration of the Pt(II) 
complex was in large excess with respect to the other reactant (X= nucleoside, RNA or 
DNA). As such, the Pt(II) concentration was included in the rate constant, which is the 
pseudo-first-order rate constant or kobs.
51
 The reaction between Pt and X is second-order, 
but a ≥50-fold excess is used. Therefore, kobs will be equal to the product of the Pt(II) 
concentration and the apparent second-order rate constant, k2,app. The apparent second-
order rate constant, k2,app is then obtained by varying the platinum concentration. 
2.2.2 Cisplatin coordination rates to H69 RNA in the presence of aminoglycosides 
Cisplatin binding to the H69 RNA hairpin loop is well characterized.
95
 The H69 
sequences with and without pseudouridine (ψ) modifications (Figure 2.2) were utilized 
in this experiment to determine the effect of the modification on aminoglycoside binding. 
Aminoglycosides such as neomycin and paromomycin (Figure 1.16) that are known to 
show interactions with the H69 region (19-mer) were used, and compared to the non-
binding compound streptomycin. 
 
Figure 2.2. Structures of RNA constructs used in the kinetic study. Modified () 
and unmodified (UUU) H69 rRNA constructs are shown, in which  is pseudouridine 





2.2.3 Structural effects of platinum compounds on DNA 
 Structural effects caused by complex 5 were evaluated by reacting it with plasmid 
DNA and a duplex DNA oligomer (22-mer). As a comparison, reactions were done with 
cisplatin. By reacting with plasmid DNA, global structural changes caused by cisplatin 
and 5 were evaluated. The effect of a single platination event within a duplex DNA was 
also evaluated using the small oligomer DNA. 
2.2.4 Structure probing of RNA 
 Single-stranded RNAs form many secondary structures and adopt complex 
scaffolds, which are important for its function.
97
 There are various interactions that can 
occur between the bases, and with ions in the solution (e.g., Mg
2+
), that govern the 
structure and are important for drug binding.
127
 Probing techniques are utilized to 
understand the key structural features of RNA at the nucleotide level. The two main 
probing techniques used for this purpose are chemical and enzymatic probing.
128
 Some 
chemical probes are able to penetrate cell membranes and therefore can be used for in 
vivo probing (e.g., DMS).
99
 These small molecules provide information about solvent-
accessible sites within complex, folded, tertiary structures of RNA.
128
 In contrast, 
enzymatic probing provides less information about the folded RNA structure, due to the 
bulkiness of the probe. RNases can be utilized to determine ligand-binding sites in in 
vitro studies. Table 2.1 shows some commonly used chemical and enzymatic probes and 
their targets. Depending on the size of the RNA, the detection method can vary. 
Modification or cleavage sites for small RNA can be directly detected by radiolabeling 
the RNA ends.
99
 For larger RNAs (over 200 nucleotides), primer extension is used to 








RNase T1 Unpaired G 
RNase T2 Unpaired A>C, U, G 
RNase V1 Paired or stacked nucleotides 
RNase U2 Unpaired A>G>>C>U 
RNase H RNA only from DNA-RNA hybrids 
Nuclease S1 Unpaired nucleotides 
Mung bean nuclease Single-strand regions 
DMS N7-G, N1-A, N3-C 
CMCT N7-G, N3-U 
DEPC N7-A 
kethoxal N1, N2-G 
Fe-EDTA (OH radicals) Ribose C1 and C4 
NMIA 2-OH of flexible nucleotides 
Pb
2+
 Phosphodiester bonds in single-stranded 
regions and unstable helices 
in-line probing Phosphodiester bonds 
DMS: dimethyl sulfate; DEPC: diethylpyrocarbonate; CMCT: 1-cyclohexyl-3-(2-
morpholinoethyl) carbodiimide metho-p-toluene sulfonate; NMIA: N-methylisatoic 
anhydride. 
 
 The use of cisplatin as a probe for RNA structure was reported recently.
43
 Reverse 
transcription-based primer extension followed by gel electrophoresis was employed to 




find compound 5 coordination sites on rRNA in this study. The ribosomes were isolated 
and platinated. Then, the rRNAs were extracted and used for primer extension reactions 
with DNA primers designed for specific regions of the ribosome. 
Figure 2.3. A schematic diagram showing the basic steps of cisplatin probing. 
Denaturing gel electrophoresis is carried out after the reverse transcription-based primer 
extension reactions. The resulting gel image will show the dideoxy sequencing lanes for 
each nucleotide control, and cisplatin reaction lanes. The red color bands in the cisplatin 
reaction lane depict the stop sites. The stop sites occur one nucleotide prior to the actual 
modification site on the RNA.  
 
2.2.5 Potency and accumulation of platinum(II) compounds in human cancer and 
normal cell lines 
The anticancer potency of 5 was tested by determining the IC50 values in several 
human cancer cell lines using the MTT colorimetric assay.
129
 This assay relies on a color 
change in which viable cells convert the yellow-colored MTT (3-(4,5-dimethylthiazol-2-






 The NAD(P)H-dependent cellular oxidoreductase enzymes in viable cells are 
responsible for the color change, as they reduce the MTT reagent to produce insoluble 
formazan.
130
 The color change can be monitored by a multi-well scanning 
spectrophotometer/plate reader.  
Scheme 2.1. The conversion of MTT to formazan. MTT is a yellow reagent and 
formazan is purple. 
 
2.3 Materials  
2.3.1 Chemicals and supplies 
Cisplatin (cis-diamminedichloridoplatinum(II)) was obtained from Alfa Aesar 
(Wardhill, MA). Anhydrous dimethylformamide (DMF) (99.8% purity) was obtained 
from EMD (Gibbstown, NJ). The HPLC grade acetonitrile, silver nitrate (AgNO3), 
ammonium acetate (NH4OAc), sodium dihydrogen phosphate (NaH2PO4), disodium 
hydrogen phosphate (Na2HPO4), KH2PO4, K2HPO4, magnesium chloride (MgCl2), 
potassium chloride (KCl), sodium chloride (NaCl), agarose, bromophenol blue dye, 
dimethyl sulfoxide (DMSO), 2-amino-2-hydroxymethyl propane-1,3-diol (Tris), phenol-
chloroform-isoamyl alcohol (25:24:1) (PCI), T4 DNA ligase, boric acid, phosphate buffer 












from Fisher Scientific (Fair Lawn, NJ) were used. The chemicals potassium 
tetrachloroplatinate(II) (K2PtCl4), sodium perchlorate (NaClO4), acrylamide, glycerol, 
xylene cyanol dye, N,N'-methylenebisacrylamide, urea, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 2-mercaptoethanol (2-ME), 3-hydroxypicolinic 
acid (3-HPA), ethylenediaminetetraacetic acid (EDTA), ammonium chloride (NH4Cl), 
ethanol, neomycin B, paromomycin, streptomycin, penicillin-streptomycin (pen-strep), 
fetal bovine serum (FBS), tissue culture dishes, and 96-well plates were purchased from 
Sigma-Aldrich (St. Louis, MO). The chemicals Luria broth (LB) (BD medical 
Technology, Franklin Lakes, NJ), deoxynucleoside triphosphates (dNTPs) (Genscript, 
Piscataway, NJ), dideoxy nucleotide triphosphates (ddNTPs) (Roche, Indianapolis, IN), 
nuclease- and protease-free sucrose (MP Biomedicals, Solon, OH) were used. DNase I 
and ImPromII Reverse Transcriptase (RT) were purchased from Promega (Fitchburg, 
WI). The enzymes T4 RNA ligase and T4 polynucleotide kinase from New England 
Biolabs (Ipswich, MA) were employed in this study. The radiolabels [5'-
32
P] pCp and 
[
32
-P] ATP were purchased from Perkin-Elmer Life Sciences, Inc. (Waltham, MA). The 
Sep-pak C18 cartridges were purchased from Waters (Milford, MA). Keratinocyte-SFM 
media, 0.25% trypsin-EDTA (Gibco, Pittsburgh, PA), and 10 ppm platinum solution in 
2% HNO3 (High-purity standards, Charleston, NC) were used for the cell-based 
experiments. RNase-free distilled, deionized water (ddH2O) was used for all experiments.  
2.3.2 Nucleosides and oligonucleotides 
Single RNA and DNA nucleosides were purchased from Sigma-Aldrich and stock 
solutions were prepared by dissolving them in ddH2O to the desired concentration (The 






Concentrations of the nucleoside solutions were calculated by measuring the absorption 





















DNA and RNA were purchased from Integrated DNA Technologies (Coralville, 
IA) and GE Dharmacon (Lafayette, CO), respectively. The DNA and RNA were gel 
purified as described in each method section. Concentrations of nucleic acid solutions 
were calculated by using the absorbance at 260 nm and single-stranded extinction 
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 The pUC19 plasmids were isolated and 
purified by using a plasmid maxi-prep kit from Qiagen (Germantown, MD). 
DNA1: 5' TCTCCTTCTTGGTTCTCTTCTC 3' 
DNA2: 5' GAAGAGAACCAAGAAGGAGAGA 3' 
RNA1: 5' UCUCCUUCUUGGUUCUCUUCUC 3' 
H69 RNA (UUU): 5' GGCCGUAACUAUAACGGUC 3' 
H69 RNA (): 5' GGCCGAACAAACGGUC 3' 
H69 primer: 5' CGACAAGGAATTTCGCTACC 3' 
790 primer: 5' ACCAAGTCGACATCGTTT 3' 
A-site primer: 5' GTTAAGCTACCTACTTCT 3' 





2.3.3 Cell lines 
The human cancer cell lines HeLa, H1299, MDA-MB-231, and MDA-MB-453 
were obtained from Dr. Young-Hoon Ahn’s lab.
134-137
 The human prostate cancer cell 
lines (DU145 and LNCaP) were obtained from Dr. K.V. Honn’s lab in the Chemistry 
Department.
138,139
 The normal prostate cell line, RWPE-1, was received from Dr. Zhihui 





HPLC analysis was performed on a Waters 600 LC, with a 717 autosampler 
(Waters, Milford, MA), UV-detector, and a Supelco Discovery C18 column (5 μm 
particle diameter; 4.6 mm i.d. × 250 mm, Sigma-Aldrich, St. Louis, MO). The LC-MS 
analysis was carried out on a Shimadzu 8040 Nexera X2 Ultra High 
Performance/Pressure Liquid Chromatograph (UPLC) system with a quadrupole type 
tandem mass spectrometer (Shimadzu, Columbia, MD). An Acquity UPLC HSS T T3 
C18 column was (1.8 μm particle diameter, 2.1 × 100 mm, Waters, Milford, MA) was 
used in LC-MS. The MALDI mass spectra were acquired on a Bruker UltrafleXtreme 
TOF (Bruker Daltonics, Billerica, MA). Whole cell platinum levels were quantified by 
using an Agilent 7700X ICP-MS, ASX-500 series ICP-MS autosampler with Agilent 
MassHunter software (Santa Clara, CA). The gel images were obtained on a Typhoon 
FLA 9500 instrument (GE Healthcare). The pH of the solutions was determined by using 
a Mettler Toledo (Columbus, OH) pH meter with an Inlab Versatile Pro pH electrode 






2.4.1 Preparation of activated cisplatin complexes 
Cisplatin (1 mg, 3.3 μmol) and AgNO3 (30 mg, 177 μmol) solutions were 
prepared by dissolving separately in 333.3 μL and 353.2 μL anhydrous DMF volumes to 
make 10 mM and 500 mM solutions, respectively.
48
 To a 200 μL of prepared cisplatin 
solution 1 equivalent of AgNO3 was added to give a 9.8 mM solution of mono-activated 
(aquated) cisplatin (compound 3). To obtain bis-activated complex, the solutions were 
mixed in a 1:2 molar ratio. The reaction mixture was shaken at 37 C for 16 h in the dark 
on a vortex mixer (Scheme 2.2). The resulting AgCl was precipitated by centrifugation at 
14,000 rpm for 10 min, and the supernatant contained the desired mono-activated 
cisplatin (3). Activated cisplatin was freshly prepared every time and diluted to 
intermediate stock concentrations with ddH2O just prior to use. 
Scheme 2.2. Generation of the mono-activated platinum species (3). One chlorido 
ligand will be removed as AgCl to yield the mono-activated species, compound 3. 
 
 
2.4.2 Synthesis and purification of cis-dichlorido[(2-β-D-glucopyranosidyl)propane-
1,3-diammine]platinum, compound 5 
Synthesis of compound 5 was done as described previously from compound 4.
82
 
Synthesis, purification, and NMR characterization of compound 4 (calculated mass 252 
Da) was done by Amr Sonousi in Dr. David Crich’s lab, Department of Chemistry, 


















solutions were prepared by dissolving in 1 mL of ddH2O. To generate 5, they were mixed 
(1:1 molar ratio, 65 μmol) and stirred at room temperature for 2 days in the dark. The 
color of the solution changed from orange to light brown. One µL of the crude product 
solution was mixed with 1 µL of saturated 3-hydroxypicolinic acid (3-HPA) matrix in 
50% acetonitrile and analyzed by MALDI in the positive mode. The product was then 
purified by HPLC on C18 (5 μm particle diameter; 4.6 mm i.d. × 250 mm, Sigma-
Aldrich, St. Louis, MO) on a Waters 600 LC with a 717 autosampler (Waters, Milford, 
MA) and UV-detector (Figure 2.4a). The mobile phases of 40 mM ammonium acetate, 
pH 6.5 (NH4OAc) (buffer A), and 40% acetonitrile (buffer B) were used. The column 
was equilibrated with 95% (v/v) buffer A and 5% (v/v) buffer B, and then the percentage 
of buffer B was increased in a linear gradient from 5 to 35% over 30 min. The product 
peak was collected, dried, and characterized by MALDI-MS (Figure 2.4b) and 
1
H-NMR 








P) 5 mm PFG 
One NMR Probe). The total dry weight of purified 5 (calculated mass 518 Da) was about 
25 mg (~75% yield) and it was light yellow in color.  
Scheme 2.3. Chemical synthesis, structure of the carbohydrate-linked cisplatin 
analog (cis-dichlorido[(2-β-D-glucopyranosidyl)propane-1,3-diammine]platinum 










Figure 2.4. Isolation and characterization of compound 5. (a) The HPLC trace (C18 
column, eluted at 3.5 min with linear gradient of B from 5 to 35% over 30 min, flow rate 
1 mL/min) for crude and purified 5. (b) The MALDI-MS spectrum for purified 5. The 
calculated mass for [compound 5+K
+
] is 556.99 Da and the observed (3-HPA matrix, 
positive detection mode) was 556.82 Da. The inset shows the isotopic distribution for 
predicted and observed complex. 
 
MALDI-MS spectrum showed a peak at 557 Da, which is the mass for 5 (518 Da) 
associated with K
+
. The isotopic distribution observed on MALDI-MS as shown is the 












Pt (25%), and 
198
Pt (7%) and Cl 
has two stable isotopes, 
35
Cl (75.8%) and 
37
Cl (24.2%). Compound 5: 
1
H NMR (600 
MHz, D2O): δ 4.36 (d, J(H1,H2) = 7.7 Hz, 1H;H1), 3.57 (m, 1H; H7), 3.72 (dd, 
J(H6a,H6b) = 12.5 Hz, J(H5,H6a) = 2.4 Hz, 1H; H6a), 3.54 (dd, J(H6a, H6b) = 12.1 Hz, 
J(H5, H6b) = 5.3 Hz, 1H; H6b), 3.10-3.33 (m, 4H; H2, H3, H4, H5), 2.51-2.61 (m, 2 × 
2H; H8, H9) (Appendix A, Figure A4). 
Mono-activation of 5 was carried out in ddH2O. A 9.8 mM solution of 5 was 
prepared by dissolving 6 mg (11.6 μmol) in 1.16 mL of ddH2O. The AgNO3 solution (500 
mM) was prepared by dissolving 30 mg in 353.2 μL of ddH2O. To obtain the mono-
activated complex, one equivalent of AgNO3 (11.6 μmol, 23.2 μL) was added to the 
solution of 5 (Scheme 2.3). The activated complex was divided into 50 μL aliquots, dried 
in a speed vac concentrator, stored in -80 °C, and redissolved in ddH2O just prior to use.  
2.4.3 Reaction of mono-activated 5 with nucleosides 
Adenosine, guanosine, cytidine, and uridine nucleoside solution stocks were 
prepared by dissolving about 2 mg in 500 μL of water, and the exact concentrations were 
determined by measuring the UV absorbance.
131,132
 The reactions were carried out by 
mixing nucleoside (0.1 mM): mono-activated 5 (0.5 mM) in a 1:5 ratio at 37 °C for 16 h 
in the dark. The reaction mixtures were quenched by adding 3 μL of 3 M NaCl and 
vortexing. The quenched reaction mixtures were analyzed by reverse-phase HPLC on a 
Supelco Discovery C18 column (5 μm particle diameter; 4.6 mm i.d. × 250 mm) on a 
Waters 600 LC with a 717 autosampler and UV-detector. The mobile phases of buffer A 




B, and then the percentage of buffer B was increased in a linear gradient from 5 to 35% 
over 30 min. 
2.4.4 Kinetic parameters for the reaction between G and dG nucleosides with Pt(II) 
complexes 
 For the kinetic measurements mono-activated cisplatin (3) and mono-activated 
compound 5 were used. Reactions were carried out by mixing sodium phosphate buffer, 
pH 7.0 (final concentration 25 mM) with freshly prepared and diluted nucleoside solution 
(final concentration 0.1 mM) and mono-activated Pt(II) (final concentration 5 mM) in a 
1:50 molar ratio. The total volume of the master reaction mixture was adjusted up to 300 
μL by adding ddH2O. The reactions were vortexed and incubated at 37 °C in the dark up 
to 6 h. At varying time points, 45 μL of sample was removed from the reaction mixture 
and quenched by adding 3 μL of 3 M NaCl (final concentration 188 mM) and vortexing. 
The quenched samples were immediately frozen on dry ice and stored at -80 °C until 
further analysis. The quenching time points were 0.5, 1, 2, 3, 4 and 6 h. This procedure 
was repeated three times for each nucleoside reaction. The samples were centrifuged at 
10,000 rpm for 10 min before injection onto the HPLC. The same HPLC method 
described in Section 2.4.3 was used, and 35 μL from each sample was injected onto the 
column. The retention times for the nucleosides were confirmed by comparing to 
standards and the peak areas (unreacted nucleoside and products) were calculated using 
Empower software (Empower Software Solutions, Inc., Orlando, FL). The pseudo-first-
order rate constants were calculated by plotting the ratio of unreacted nucleotides over 
quenching times. HPLC standard calibration curve for G (from Bett Kimutai) is shown in 




Scheme 2.4 shows the kinetic model for a reaction between X (nucleoside, RNA, 
or DNA) and Pt(II) under pseudo-first-order reaction conditions. The reaction between 
the Pt(II) complex and X was considered to be a second-order reaction as shown in 
Equation 2.1.
51
 To maintain pseudo-first-order conditions, high Pt(II) concentrations 
were used, in which a ≥50-fold excess over X was used (the specific concentrations are 
mentioned in the Methods section for each experiment).
47
 Therefore, kobs was equal to the 
product of the Pt(II) concentration and apparent second-order rate constant, k2,app 
(Equation 2.2). To experimentally obtain kobs, the unreacted RNA ratio [Xt]/[X0] and 
time were plotted to fit an exponential decay (Equation 2.3), in which the m2 
corresponded to kobs.  
Scheme 2.4. Kinetic model for the reaction between Pt(II) complexes and X, in 
which X can be nucleosides, RNA or DNA. 
2.4.5 Product characterization by LC-MS 
 The dG or G and mono-activated 5 reaction mixtures from Section 2.4.4 (after 16 
h reaction) were analyzed on LC-MS or by direct injection onto a mass spectrometer 
Pt(II) + X                                          Pt-X                  X= nucleoside, RNA, or DNA 
-d[X]/dt   =  k
app  
[Pt(II)] [X]                                                     Equation 2.1  
Under pseudo-first-order conditions, 
-d[X]/dt   =  k
obs  
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Y= m1 exp (-m2X)+m3, in which Y= [Xt]/[X0], m2= kobs, m1= amplitude of the 









(details below). The analysis was carried out on a Shimadzu 8040 Nexera X2 Ultra High 
Performance/Pressure Liquid Chromatograph (UPLC) system with a quadrupole type 
tandem mass spectrometer (Shimadzu, Columbia, MD). The sample was introduced and 
ionized by using an electrospray ionization (ESI) probe (nebulizing gas flow 3 L/min, 
drying gas flow 15 L/min, interface 4.5 kV, heat block temperature 400 °C).  An Acquity 
UPLC HSS T T3 C18 column (1.8 μm particle diameter, 2.1 × 100 mm, Waters, Milford, 
MA) was used, and the column oven was maintained at 40 °C. For the LC buffers, 10 
mM NH4OAc, pH 5.2 (buffer C), and 10 mM NH4OAc (10%) in 10% acetonitrile (buffer 
D) were used. Elution was carried out with a flow rate of 800 μL/min, from 100 to 67% 
buffer C and increase in D from 0 to 33% over the course of a 17 min gradient. For direct 
injection, 2 μL of the reaction mixture was introduced to the mass spectrometer with a 
flow rate of 300 μL/min using buffer D. Peaks were identified by using LabSolutions 
software.  
2.4.6 Ethanol precipitation of nucleic acids 
 To a centrifuge tube containing nucleic acid solution (V volume), 2.5 V of 100% 
ethanol and 0.1 V of 3 M NH4OAc were added and the sample was placed on dry ice for 
45 min. The sample was then centrifuged at 14,000 rpm for 45 min at 4 °C. The 
supernatant was carefully removed and 100 μL of 70% ethanol was added to the pellet. 
The sample was placed on dry ice for 15 min and centrifuged at 14,000 rpm for 15 min at 
4 °C. The supernatant was removed and the remaining pellet was dried in a speed vac 






2.4.7 Radiolabeling of the RNA at the 3' end and purification 
The 3' end of each H69 RNA (UUU and ) was radiolabeled using [5'-
32
P]-
pCp and T4 RNA ligase.
141
 For the radiolabeling RNA (50 pmol per reaction), 10 μCi of 
[5'-
32
P]-pCp, 30 units of T4 RNA ligase enzyme, 3 μL of 10× ligase buffer (50 mM Tris-
HCl, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol), 4 μL of DMSO, and ddH2O (total 
volume is 30 μL) were used.  Following a 16 h incubation time at 4 °C, the labeled RNA 
was ethanol precipitated and gel purified on a 20% denaturing polyacrylamide gel (0.8 
mm thick, acrylamide: bisacrylamide 19:1, 1× TBE). Following PAGE, the RNA bands 
were visualized by autoradiography, excised, and eluted by the crush-and-soak method in 
350 mM NaOAc, pH 5.3, 0.1 mM EDTA buffer overnight at 4 °C.
142
 Desalting of the 
purified RNAs was carried out using Sep-pak C18 columns.
132
 The eluted RNA was dried 
in a speed vac concentrator. The dried nucleic acid pellet was dissolved in 50 µL of 
ddH2O by vortexing.  
2.4.8 Radiolabeling of nucleic acids at the 5' end
143
 
For the labeling of 50 pmol DNA or RNA, 10 μCi [γ-
32
P] ATP and 10 units T4 
polynucleotide kinase were reacted in 3 μL of 10× T4 polynucleotide kinase buffer (50 
mM Tris·HCl, pH 7.6, 10 mM MgCl2, 5 mM DTT, 0.1 mM spermidine, and 0.1 mM 
EDTA). The total volume was adjusted to 30 μL with ddH2O and the sample was 
incubated at 37 
o
C for 45 min. The labeled nucleic acid was isolated by gel purification as 
described for 3' labeling followed by desalting.  
2.4.9 Platination rates for the reactions with oligonucleotides  
The DNA1 and RNA1 strands were used for kinetic experiments. The unlabeled 




cpm) were mixed with buffer (final concentration of 12 mM K
+
 and 20 mM Na
+
, pH 6.2) 
and ddH2O to a volume of 50 L in an 0.6 mL centrifuge tube, placed in a boiling water 
bath for 2 min, and then on ice for 5 min. The reaction was then spun down and allowed 
to reach room temperature before adding the Pt(II) compound. The sample was then 
incubated with mono-activated Pt(II) complex (final concentration of 94 M) at 37 C in 
the dark. The total volume of the reaction mixture was 60 μL. The reactions were 
quenched at different time points by taking 5 μL aliquots and putting into a tube 
containing 1 L of 2 M NaCl, followed by freezing of the samples on dry ice. A control 
reaction was also carried out by adding water instead of the platinum compound. To each 
reaction 0.4 L of loading buffer that contains 0.1% bromophenol blue, 0.1% xylene 
cyanol, 1× Tris base, boric acid, EDTA, and 8 M urea was added, and the solutions were 
loaded onto a 20% polyacrylamide gel (0.4 mm thick, acrylamide: bisacrylamide 19:1, 1× 
TBE) and run at 48 V/cm for about 3 h. The gel image (illustrated in Figure 2.5a) was 
analyzed and the unreacted nucleic acid was quantified using ImageQuant
TM
 software 
(GE Healthcare) using the following Equation 2.4. 
Equation 2.4: 
Fraction of unreacted RNA ([Xt]/[X0]) 
  
                                             
                                                                 
 
 Kaleidograph 4.1 software was used to plot the fraction of unreacted nucleic acid 
over time to obtain the platination rates (Figure 2.5b). Each reaction rate was obtained by 
averaging three trials. For comparison, experiments were carried out with bis-activated 




were obtained in a 12 mM K
+
 and 5 mM Na
+
, pH 6.2 buffer. Each reaction rate was 
obtained as an average from three trials. 
 
Figure 2.5. Schematic diagram of the gel and graph for kinetic experiments. (a) A 
schematic of the electrophoretic mobility shift assay is shown. The quenched reactions 
are loaded onto a 20% denaturing polyacrylamide gel and the products and reactants are 
separated and quantified. The concentration of unreacted RNA decreases over time from 
t0 to tt. (b) A representation of the exponential decay of the reactant over time. 
 
2.4.10 Cisplatin coordination rates to H69 RNA in the presence of aminoglycosides 
The basic kinetic experiment protocol described in Section 2.4.9 was followed for 
this experiment. The labeled (50,000-60,000 cpm) and unlabeled H69 hairpins (final 
concentration of 0.7 M) were incubated with freshly prepared aminoglycoside (final 
concentration 1, 3, or 6 M) at 37 C for 30 min in buffer (final concentration of 12 mM 
K
+
 and 20 mM Na
+
, pH 6.2) and water. This step was followed by incubation with mono-
activated cisplatin (final concentration of 188 M) at 37 C in the dark as described 
above. The final volume of the reaction mixture was 60 μL. The experiment was repeated 
three times to obtain each rate for neomycin, paromomycin and streptomycin at 1, 3, and 
6 M concentrations.  
2.4.11 Platinum complex reaction with plasmid DNA 
The pUC19 plasmids were isolated by QIAGEN Plasmid Maxi Kit following the 
user protocol. Reaction tubes were prepared containing 0.5 µg of DNA plasmid, 10 mM 




platinated with either freshly mono-activated cisplatin (final concentration of 160 µM) or 
compound 5, separately. The reactions were incubated at 37 C in the dark for 24 h. At 
varying time points, reactions were quenched by adding 3 µL of 3 mM NaCl and 1 µL of 
loading dye (0.25% bromophneol blue, 0.25% xylene cyanol, 30% glycerol). A control 
reaction was also prepared without adding Pt(II) compound. The quenched reactions were 
then loaded on to a 1.2% agarose gel and ran at 75-80 V until the xylene cyanol dye band 
has migrated off the gel. 
2.4.12 Platinum complex reaction with duplex DNA oligomer 
A model DNA was chosen to examine the impact of platination on DNA 
bending.
24
 The DNA1 (3 nmol) was platinated with bis-activated cisplatin, or 5 (6 nmol), 
by reacting in a 1:2 ratio, then the products were purified and desalted by using 20% 
polyacrylamide gel electrophoresis and ethanol precipitation as described earlier. 
Platinum adduct formation was confirmed by MALDI-MS. For that, 2 µL (300 pmol) of 
platinated DNA was mixed with 1 µL of saturated 3-hydroxypicolinic acid (3-HPA) 
matrix in 50% acetonitrile, spotted on a MALDI plate, and allowed to dry. The mass 
spectra were acquired on a Bruker UltrafleXtreme TOF (Bruker Daltonics, Billerica, 
MA) instrument in the positive-ion reflector mode.
95
 
The 5' end of the DNA2 strand (50 pmol) was radiolabelled using [-
32
P] ATP, 
gel purified, and desalted as described in Section 2.4.8. For the annealing reaction, 
60,000-100,000 cpm from the radiolabelled DNA2 strand and 20 pmol from platinated 
DNA1 strand were used. A control reaction was done with unplatinated DNA1 as well. 
The total reaction volume was adjusted to 10 µL with deionized water and the reaction 




over 6 h, and then the temperature was further reduced to 4 °C and held constant for an 
additional 2 h by keeping in the cold room. To the annealed oligomer (10 µL), 1 µL of 10 
mM ATP, 2 µL of 10× T4 DNA ligase buffer (400 mM Tris-HCl, 100 mM MgCl2, 100 
mM DTT, 5 mM ATP, pH 7.8), and 1 unit of T4 DNA ligase were added. After adjusting 
the total volume to 20 µL with water, the ligation reaction was allowed to proceed for 1 h 
at room temperature. The ligation reactions were loaded onto an 8% native 
polyacrylamide gel (0.8 mm thick, mono:bisacrylamide ratio of 29:1, 1× TBE, 10 min 
pre-run) and run (89 mM Tris-borate, 89 mM acid, 2 mM EDTA) at approximately 10 
V/cm for 5 h until the bromophenol blue dye marker had migrated off the gel. A water-
cooled electrophoresis apparatus was used to maintain the temperature of the gel at room 
temperature. Migration of all the DNA bands in the original autoradiogram was measured 
manually and used for the bend angle calculations. A calibration curve for distance 
migrated over the length (bp) was plotted for the unplatinated control. Using the 
calibration curve, calculated lengths were obtained for the platinated oligomer bands with 
reduced mobility. The relative mobility (RL) of the platinated DNA (the ratio between the 
calculated length of the oligomer and actual length (L)) was calculated for the 110 or 132 
bp sized oligomers. Determination of the DNA bend angle was performed using the 




- 0.47) (RC), in which L represents the length of a 
particular oligomer with relative mobility RL and RC is the curvature relative to DNA 
bending of an A tract (A DNA with a known bend angle).
24,144,145
 The detailed 
calculations with the results are discussed in Chapter 4. 
2.4.13 Isolation of 70S ribosomes and ribosomal subunits  




strain by using the sucrose gradient method.
146
 E. coli was grown to 0.4 OD and the 
culture was centrifuged at 6,000 g for 20 min to pellet the cells. The pellet was 
resuspended in buffer A (20 mM HEPES-KOH, pH 7.5, 100 mM NH4Cl, 10 mM MgCl2, 
and 0.5 mM EDTA) and lysed on a French Press. After adding DNase I (5 μg/mL), the 
lysate was incubated on ice for 15 min. The lysate was centrifuged twice at 15,000 rpm 
for 30 min and the supernatant was collected. After adjusting the NH4Cl concentration in 
the supernatant to 500 mM, the sample was centrifuged at 42,000 rpm for 4 h to pellet the 
crude ribosomes. The pellet was washed and resuspended in buffer B (20 mM HEPES-
KOH, pH 7.5, 200 mM NH4Cl, 1 mM MgCl2). The concentrations of the crude ribosomes 
were determined by using a Nanodrop UV-visible spectrometer. About 30 OD of crude 
ribosomes were layered on 40 mL of a 10-30% sucrose gradient in buffer B with 1 mM 
MgCl2 and centrifuged in a swinging bucket rotor on a Sorvall WX 80 ultra centrifuge at 
19,000 rpm for 19 h. The ribosomes and subunits were collected separately. Fractions of 
the same type were combined and the Mg
2+
 concentration was raised to 10 mM.  
Ribosomes were pelleted by centrifugation at 42,000 rpm for 24 h at 4 °C. Pure 
ribosomes were redissolved in storage buffer (ribosome subunit stock buffer: 20 mM 
HEPES-KOH, pH 7.5, 10 mM MgCl2, 30 mM KCl; full ribosome stock buffer: 20 mM 
HEPES-KOH, pH 7.5, 6 mM MgCl2, 30 mM NH4Cl) and stored at -80 °C.  
2.4.14 Platination of ribosomal RNA and rRNA purification 
For each reaction, 15 pmol of ribosomes/subunits were used. Platination was 
carried out by reacting mono-activated platinum(II) compounds with ribosomes/subunits 
in 1:200 pmol ratio for 16 h at 37 °C in the dark (72 mM HEPES, pH 6.5, 3.6 mM 




precipitation. Phenol-chloroform extraction with 10 mM EDTA was done to extract the 
reacted rRNA followed by ethanol precipitation. Isolated rRNA was dissolved in ddH2O 
and the concentration was determined using a Nanodrop UV-visible spectrometer (1 OD= 
23.5 pmol of 70S rRNA, 1 OD= 69 pmol of 30S rRNA). 
2.4.15 Reverse –transcription and primer extension reactions 
The appropriate DNA primers were radiolabeled with [-
32
P] ATP at the 5' end as 
described earlier. Platinated rRNA (500 ng) and 1 µL of radiolabeled primer (60,000-
100,000 cpm) were incubated together at 80 °C for 3 min and then allowed to cool down 
to room temperature for 5 min. The master mixture for a reverse transcription reaction 
was prepared by mixing 24 units of ImProm-II reverse transcriptase enzyme, 1 μL of 5× 
reverse transcriptase reaction buffer, and 0.4 μL of 50 mM MgCl2. To the primer-
annealed platinated rRNA, 1.65 μL of the master mixture, 1 μL of dNTP (stock 
concentration 10 mM), and ddH2O (total volume 5 μL) were added. Primer extension was 
carried out at 43 °C for 1 h. For sequencing, total RNA was used with the corresponding 
radiolabeled primer. For the sequencing reverse transcription reaction 1 μL of 
dNTP:ddNTP 1:4 (0.5 mM:2 mM) was used instead of the dNTP mixture. Termination of 
the reactions was done by heating the reaction mixture at 95 °C in a water bath for 2 min 
after adding 2 μL of denaturing loading dye (80% formamide, 1× TBE, 0.02% 
bromophenol blue, 0.02% xylene cyanol) and quickly placing on ice. Reactions (50,000 
cpm per lane) were loaded into 10% denaturing polyacrylamide gels (0.4 mm thick, 
acrylamide:bisacrylamide 19:1, 0.5× TBE, 7 M urea). Gels were run at 33 V/cm, for 
approximately 3 h. Gels were exposed to a phosphor screen overnight and imaged on a 




2.4.16 Initiate cell growth from a frozen stock  
 Autoclaved tips and tubes were used at all experiments. The experiments were 
carried out in a Laminar floor hood under aseptic conditions to avoid contaminations.  
Sterile media and solutions were used for the cell growth and assays and 70% ethanol 
was used to wipe the surfaces. Cancer cells were grown in Dulbecco’s Modified Eagle’s 
(DMEM) medium with heat inactivated 10% FBS and penicillin (5 units/mL) and 
streptomycin (5 units/mL) as antibiotics. For the normal cells, keratinocyte media 
containing prequalified human recombinant epidermal growth factor 1-53 (EGF 1-53) 
and bovine pituitary extract (BPE) was used. The media, solutions, and the enzymes were 
stored at 4 °C and thawed at 37 °C water bath prior to use. All of the cultures were 
incubated in a humidified, 37 °C, 5% CO2 incubator. 
 Frozen vials containing the cells were removed from the liquid nitrogen freezer 
and immediately thawed by placing in a 37 °C water bath for 1-2 min. The thawed cells 
were transferred to a sterile centrifuge tube containing 1 mL medium and centrifuged for 
5 min at 200 × g. The supernatant was discarded and the pellet was resuspended by 
adding 1 mL medium. It was then transferred to a culture plate that contains appropriate 
amount of medium and incubate at 37 °C to let the cells attach to the plate. The cells were 
monitored and the medium was changed after 5-6 days. The cells were grown until they 
reach confluency. 
 2.4.17 Trypsinizing and subculturing cells from a monolayer 
 After reaching 80-90% confluency, cells were dispersed by trypsin treatment and 
reseeded onto new plates. The medium was removed from the primary culture and PBS 




for normal cells) was added and incubated at 37 °C for about 10 min to dislodge the 
adhered cells. Tapping on the culture dish facilitated dislodging as well. Cells were 
observed under the microscope to ensure that the cells are detached. For cancer cells, 
small volume of medium containing FBS was added to the plate to inactivate trypsin, and 
mixed by pipetting to make a homogenous cell suspension.  For normal cells, after adding 
FBS containing medium, cells were transferred to a centrifuged tube and centrifuged for 
2 min at 200 × g. Supernatant was removed and the pellet was resuspended in 
keratinocyte media. Equal volume of the cell suspension was added to fresh plates with 
media and incubated at 37 °C in a 5% CO2 incubator. The media was changed as needed 
and the cells were grown to confluency. 
2.4.18 The anticancer potency of compound 5 using MTT assay  
 After reaching the confluency, the cells were trypsinized and collected in a 15 mL 
centrifuge tube. The total volume was adjusted to 5 mL by adding medium and mixed 
well by pipetting. From the cell suspension 10 μL was taken and placed on the 
hemocytometer to count the cell number under the microscope. Cancer cells 
(10,000/well) were seeded in a transparent flat-bottom 96-well plate with medium. Cells 
were grown for 24 h to allow them attached the plate. After that, the media was removed 
and fresh media and varying concentrations of the platinum compounds were added to 
the wells. Two controls were done with each experiment. A growth control well had cells 
and media, but no platinum compounds, whereas blank control wells had only media. 
After 72 h of incubation, 10 μL of MTT stock (5 mg/mL) was added to all the wells and 
incubated for additional 4 h. Then media was removed and 200 μL of DMSO was added 




optical density of each well was measured at 520 nm using a microplate reader (BioTek 
synergy H1 hybrid reader BioTek instruments, Winooski, VT). For each drug 
concentration, % cell viability was calculated using the following equation. 
Equation 2.5: 
                  
                                                 
                                                
 
The IC50 value was obtained by plotting the % viability against the drug 
concentration, in which IC50 is the drug concentration that gives the 50% cell viability. 
Each experiment was repeated two or more times in parallel to obtain the IC50 values.  
2.4.19 Quantify the platinum levels in the cells by ICP-MS  
 Accumulated Pt in the human cells was quantified by using an Agilent 
Technologies 7700 series ICP-MS instrument (Santa Clara, CA). Platinum levels in 
human prostate cancer cell line, DU145 and normal prostate cell line, RWPE-1 were 
quantified for comparison. The cells were grown in a monolayer until confluency, 
trypsinized, and homogenized. From the cell suspension, an equal number of cells 
(460,000) were seeded onto 6 cm culture dishes and grown for 18 h. The media was 
removed and the cells were washed with PBS. To each plate, platinum compound 
solution (final concentration of 50 μM) and keratinocyte media was added to give a 
volume of 3 mL. The cells were incubated for 2 h at 37 °C. The media was removed, 
cells were collected into centrifuge tubes by trypsinizing, and washed with PBS. 
Homogenized cell solutions were prepared by mixing, and cell number in each tube was 
counted by using a hemocytometer. Then, the cells were digested by adding 300 μL of 
concentrated nitric acid and incubating at room temperature for 16 h. The samples were 




solutions with 0.5, 1, 5, 10, 25, 50, 100, 200 ppb concentrations was prepared in 2% 
HNO3 and 0.5% HCl solution for calibration. Two independent trials for each cell line 
were carried out simultaneously for cisplatin and compound 5. The digested cell samples 
were analyzed in the ICP-MS along with solvent blanks, no-drug blank, and standards 
(plasma gas flow 15 L/min, nebulizer pump speed 0.3 rps, spectrum acquisition mode, 
100 sweeps per sample, 3 replicates per sample, general purpose plasma mode). The 
instrument was calibrated with 10 ppb internal standard solution that contains 
209
Bi. The 





 The data were obtained under high energy He tune mode in which the 
internal standard signal was stable and the R value for the calibration curve was 1. 












CARBOHYDRATE-LINKED PLATINUM COMPOUND: PRODUCT 
CHARACTERIZATION AND KINETIC STUDIES WITH NUCLEOSIDES 
 
3.1 Abstract 
When it comes to new drug development, an understanding of the mode of action 
is needed to refine the therapeutic approaches to further enhance efficacy. This thesis 
work focuses on a novel class of cisplatin-derivatives, carbohydrate-linked platinum 
complexes, due to their reported higher cell potencies, tumor selectivity, and low toxicity. 
To get insight into the behavior of glycoconjugated platinum(II) complexes compared to 
cisplatin, cis-dichlorido[(2--D-glucopyranosidyl)propane-1,3-diammine] platinum(II) 
(compound 5) was utilized. First, the binding preference of compound 5 was established 
by reacting it with DNA and RNA nucleosides and analyzing the products by HPLC and 
LC-MS. The compound reacted more with guanosine (G) and deoxyguanosine (dG) over 
other nucleosides. To further characterize the differential reaction rates, HPLC-based 
kinetic experiments were carried out with dG and G nucleosides and mono-activated 5 
and compared to mono-activated cisplatin. Overall, 2.5-fold or lower reaction kinetics for 
compound 5 were observed compared to cisplatin. The reduced coordination rates of 5 
compared to cisplatin are likely the result of steric hindrance from the bulkier sugar group 
at the site of reaction. Perhaps surprisingly, compound 5 showed a higher coordination 
rate with the RNA nucleoside G compared to the corresponding DNA nucleoside dG. 








 Chemotherapy along with radiation therapy is the most common way to treat 
cancer.
149
 Chemotherapeutics include alkylating agents (e.g., busulfan, chlorambucil, 
carmustine), hormones, antitumor antibiotics, and metal complexes such as cisplatin.
150
 
Among them, cisplatin and platinum-based drugs have received much attention due to 
their successful cure rates.
7
 As a result, a large number of Pt-based and other metal-
containing complexes have been synthesized in the hope of finding better drugs.
7
 Most 
studies are focused on finding drugs with low side effects, and compounds with higher 
cytotoxicity, efficacy, and selectivity towards tumors compared to normal cells. A 
characteristic feature of platinum-based complexes is that the leaving- and/or non-leaving 
group ligands can be replaced with a variety of functional groups. These ligands 
determine different aspects of the compound.
73
 Careful selection of the ligands facilitates 
tuning of cytotoxic characteristics of the complex. Carbohydrates are a class of tunable 
molecules that can serve as ligands and introduce a variety of favorable chemical 
properties to platinum complexes.
150,151
  
 Carbohydrate moieties are components of antibiotics (e.g., aminoglycosides, 
vancomycin), antivirals (e.g., ribavirin, stavudin), as well as antitumor (e.g., doxorubicin, 
bleomycin) drugs.
152,153
 One of the reasons these functionalities are widely used in drugs 
is that they help reduce toxicity and improve molecular targeting.
150
 The hydrogen-
bonding capability of carbohydrates leads to improved water solubility of the molecules. 
Carbohydrates are essential molecules in biological systems and therefore tend to be 
nontoxic. Carbohydrate attachments facilitate drug binding to specific targets such as 
ribosomes.
153






 Glucose and other monosaccharides in the body are transported 
through cell membranes via facilitated diffusion by using a family of 14 transport 
proteins called GLUTs.
155
 These transporters are highly expressed in metabolically active 
cells such as cancer cells.
126,156
 Therefore, sugar pendants can direct the drugs to tumor 
cells for higher uptake.
83
 One phenomenon that is crucial for tumor growth and 
progression is cell-cell recognition through carbohydrate-protein interactions.
157
 Modified 
carbohydrates can interfere with these interactions and inhibit cancer growth.
157
 
Moreover, carbohydrates have functional groups that can be easily modified to introduce 
amino, thiol, and carboxylato groups. Modifications allow carbohydrates to serve as 
strong donor ligands that are capable of coordinating to metals. Specifically, in platinum-
based anticancer agents, the non-leaving group ligands are usually N-donor ligands 
(Figure 3.1). Thus, if the carbohydrates are to be attached as non-leaving groups, often 
they are modified with an amino group that can be used to coordinate to a platinum 
center.
151
 The nature of the ligand influences the activity of the drug against different 
types of cancer, which will be briefly discussed in this section in regards to binding 
preferences. 
 Interest in exploring sugar conjugation for platinum-based anticancer drug 
development began about a decade after cisplatin was approved as a drug by the FDA.
84
 
Tsubomura and co-workers synthesized the first amino sugar-platinum complexes with 
promising anticancer activity against Sarcoma 180 in mice (Figure 3.1a).
84
 Figure 3.1b 
shows simple diaminosugar-platinum complexes with a 2,3-diamino-2,3-dideoxy-D-
glucose non-leaving group and different leaving groups. The cytotoxicity of these 




CH1 (ovarian), HeLa (cervical), SW480 (colon), and U2OS (bone) human cancer lines, 
however the cytotoxicities were not significantly improved compared to clinically 
available Pt-based drugs.
158
 More recently, polynuclear Pt(II) complexes with higher 
water solubility and cytotoxicities compared to cisplatin have been reported (Figure 
3.1c).
159
 The concept of attaching a known drug to sugar-platinum complexes has also 
been explored to generate multifunctional drugs.
160
 This strategy was developed to 
overcome resistance problems by linking two anticancer drugs such as doxorubicin and a 
cisplatin derivative (Figure 3.1d); however, no advantage over the individual drugs was 
observed in that case. To improve the drug-receptor interactions, sugars have also been 
attached to the Pt center via linkers.
161
 Oxaliplatin derivatives with various linkers 
attached to the 6
th
 position of glucose (Figure 3.1e) have been shown to be taken up 
selectively by GLUT1.
83
 In this study, longer linkers were shown to inhibit cell uptake, as 
they could restrict the transporter conformational changes.
83
  
Another class of carbohydrate-Pt complexes that were recently developed and 
tested were Pt(IV) complexes. These complexes are kinetically inert and therefore more 
stable for oral administration.
162
 With the axial ligands, more functionalities can be 
introduced to the drug to increase cellular accumulation, reduce side effects, and drug 
resistance.
162
 Recently, several glycoconjugated Pt(IV) complexes have been reported in 
which sugar derivatives were introduced as axial ligands for targeted cancer therapy 
(Figure 3.1f ).
163,164
 For an example, the compound shown in Figure 3.1f has shown 
GLUT1 and OCT transporter-dependent selective accumulation in cancer cells over 
normal cells and a significantly higher antitumor activity (over 150-fold) compared to 








Figure 3.1. Examples of different types of sugar-platinum complexes. Structures of 
diaminosugar-Pt(II) complexes (a and b), a polynuclear Pt(II) complex (c), Pt(II)-
doxorubicin complex (d), an oxaliplatin derivative with glucose attached to the Pt(II) 
center via a methylene linker (e), a sugar-Pt(IV)  complex (f ), and compound 5 (g) are 
shown. 
 
As explained with some examples in this section, a variety of glycoconjugated-Pt 
complexes have been synthesized and studied extensively. These studies are mainly 
confined to cellular cytotoxicity assays and have shown promising activity. A few 
attempts have been made to elucidate the transporter dependence and cancer cell 
selectivity of the glycoconjugated-Pt(II) complexes.
81,83,115,121,165
 Although these studies 
show a promising strategy for cancer treatment, detailed reactivity and structural impacts 
of a glycoconjugated-Pt complex with nucleic acids are mostly unknown. Therefore, the 
(a) (b) (c) 



































work described in this thesis attempts to understand the behavior of a glycoconjugated-
Pt(II) derivative in terms of the reactivity preferences with nucleosides, reaction rates 
with nucleosides and oligonucleotides, and structural effects on DNA. 
The carbohydrate-linked cisplatin derivative, cis-dichlorido[(2-β-D-
glucopyranosidyl)propane-1,3-diammine]platinum(II) that is been explored in this thesis 
work has a short 2-propane-1,3-diamine linker between the sugar and the platinum center 
(compound 5, Figure 3.1g).
82
 As observed in a crystal structure, the complex has a 
normal square planar geometry for the Pt(II) center with usual (compared to cisplatin) 
Pt−Cl and Pt−N distances (231 and 202 pm, respectively).
82
 Both the glucopyranose ring 
and the chelate ring adopt a chair conformation. In another study, the solution structure of 
5 was determined by NMR in D2O,
161
 revealing similar structures in both the solid and 
solution states. Furthermore, the NMR study showed that the carbohydrate moiety is in 
the axial position of the six-membered chelate ring.
161
 Compound 5 has a solubility of 
>20 mg mL
-1






Although many examples of platinum complexes bound to sugars are 
known,
150,151
 only a few reports focus on the role of the carbohydrate moiety on the 
reaction kinetics with nucleosides and target site identification on larger oligonucleotides. 
In general, platinum(II) complexes show preferences towards guanine bases. However, 
there are a few variants with known preferences towards the adenine base.
88
 One 
objective of the work in this chapter was to conduct a study with nucleic acid building 
blocks to evaluate the reactivity of compound 5 compared to cisplatin. After determining 




reaction rates of mono-activated 5 towards DNA and RNA nucleosides, dG and G, 
respectively. Another objective was to compare mono-activated compound 5 reaction 
rates with that of cisplatin. Finally, the platination products were characterized by using 
mass spectrometry to determine the adduct types (i.e., monoadducts vs. biadducts). 
Overall, in this work I investigated the kinetics and binding stoichiometry of a 
carbohydrate-linked platinum(II) complex (5) with the nucleic acid building blocks. 
3.4 Results and discussion 
 Compound 5 was synthesized and characterized as described previously (Chapter 
2, Section 2.4.2). The MALDI-MS spectrum show a peak at 557 Da, which is the  
predicted mass for 5 (518 Da) associated with K
+
. The peak patterns in the 
1
H-NMR 
spectra for the ligand (compound 4) and Pt(II) complex (5) are consistent with the 
literature (Figure 3.2, Appendix A, Figure A2-A4).
82,161
 Clear peak shifts are observed 
after coordination for protons at C7 (4.20 to 3.57 ppm), and C8 and C9 (2.96-3.20 to 2.55 
ppm), which correspond to a shift of 0.63 ppm and 0.41-0.65 ppm, respectively. In the 
six-membered chelate ring, the C7, C8, and C9 protons are closer to the Pt center; 
therefore, electron localization causes the protons to be shielded more in 5 than in the free 
ligand, 4, leading to the observed upfield shifts and supporting complex formation. Minor 








Figure 3.2. The 
1
H-NMR spectra of (a) compound 4 and (b) compound 5 in D2O 
(600 MHz). The C atoms are numbered in the chemical structures (left) and the 
corresponding proton signals are shown in the spectra. Signals that show significant peak 
shifts are marked with an asterisk (*).  
 
3.4.1 Reactivity with nucleosides 
 Cisplatin and many other platinum-based drugs are known to react with purine 
bases, adenine and guanine.
166
 Higher reactivity is usually observed with guanine. 
Initially G and dG were reacted with a 5-fold excess of mono-activated 5 for 5 h at 37 °C 
in ddH2O, pH 7.6 to detect the reactivity, and a higher peak intensity (compared to when 
buffer was used) with G was observed compared to dG. Therefore, RNA nucleosides 
were used to identify the reactivity preference; mono-activated 5 was reacted with 
adenosine (A), guanosine (G), cytidine (C), and uridine (U) under identical conditions. 




quenched with NaCl after 16 h, and then the products were analyzed by HPLC (Figure 
3.3).  
 
Figure 3.3. HPLC analysis of RNA nucleoside reactions with mono-activated 
compound 5. HPLC spectra (C18 column; buffer A: 40 mM ammonium acetate, pH 6.5; 
buffer B: 40% acetonitrile; linear gradient of B from 5 to 35% over 30 min; flow rate 1 
mL/min) for control (top) and reactions (bottom) with (a) guanosine, (b) adenosine, (c) 
cytidine, and (d) uridine nucleosides are shown. Arrows show the possible adducts for the 
reactions. 
 
Additional peak formation at higher retention times is mainly observed with G but 
not with other nucleosides, A, C, and U. For the reaction with G, four major peaks 
corresponding to possible platinum adducts are detected with 20.4, 22.4 (two unresolved 
peaks), and 27.5 min retention times with minor peaks at 19.7 and 24.2 min. Product 
formation with 5 is observed with A (27-28 min) and C (4.2 min) to a minor extent, but 




with G to a higher level than with other nucleosides. The presence of multiple adducts 





), or bis-substitution. For cisplatin, the dG binding preference 
at the N7 position was explained by the ability to form a hydrogen bond between the 
ammine-NH of cisplatin and the O6 of guanine base, which stabilizes the adduct.
167
 The 
bidentate sugar ligand of compound 5 has two H-donor ammine groups that can engage 
in hydrogen bond formation with the O6 of guanine. Therefore, as with cisplatin, we 
propose that compound 5 binding to the N7 position of guanine would be preferred over 
other nucleosides based on the potential hydrogen-bonding interaction with the O6 of 
guanine.  
3.4.2 Kinetic experiment with G and dG nucleosides  
 Cisplatin is well known to bind to DNA, and the direct coordination step is under 
kinetic control.
15
 Preference in reactivity may be governed by the non-leaving ligand, 
size, and charge. As shown by the initial reactions, compound 5 appears to have preferred 
reactivity towards G over the other RNA nucleosides, A, C and U. Therefore, HPLC 
analysis was used to quantify the coordination rates for G compared to dG. The rates for 
dG or G reactions with mono-activated 5 were compared to those with cisplatin. The 
kinetic reactions were carried out under pseudo-first-order conditions, in which the Pt(II) 
concentration was 50 times higher than the nucleoside concentration (Chapter 2, Section 
2.4.4).
47
 The reactions were quenched at 0.5, 1, 2, 3, 4, and 6 h time points with NaCl 
(final concentration 188 μM).
47
 The HPLC traces are shown in Figure 3.4a. The products 




The disappearance of nucleosides was quantified rather than appearance of 
products since multiple products are observed.  The fraction of unreacted nucleoside (y= 
unreacted nucleoside/total nucleoside) was obtained by integrating the peak areas of the 
products and reactant nucleosides. The fraction of unreacted nucleoside was plotted with 
quenching times and fit to Equation 2.3 (y= A e
-kobst) (Figure 3.4b) to obtain the pseudo-
first-order rate constants (Table 3.1). 
Figure 3.4. Results for the kinetic experiments with mono-activated Pt(II) and dG 
and G. (a) HPLC traces for the kinetic experiments with mono-activated 5 are shown. 
The reactions ([nucleoside]= 0.1 mM, [Pt(II)]= 5 mM, 25 mM Na2HPO4/NaH2PO4, pH 7, 
37 °C) were quenched at 0.5, 1, 2, 3, 4, and 6 h and injected onto the HPLC (C18 
column, linear gradient of B from 5 to 35% over 30 min, flow rate 1 mL/min). (b) Plots 
of the fraction of unreacted nucleoside (y) over time with fits to y= A e
-kobst equation are 




Table 3.1. Pseudo-first-order rates for the reactions of mono-activated Pt(II) 


















dG 49 ± 1 5 ± 0.2 
G 28 ± 2 11 ± 0.8 
                  The errors were calculated from three independent  
                  experiments. 
 
Overall, mono-activated compound 5 show lower reaction kinetics compared to 
cisplatin; for dG, the rate is 9.8-fold lower, and for G it is 2.5-fold lower (Table 3.1). 
Slower kinetics have been observed previously for platinum(II) compounds with larger 
ligands, likely due to crowding at the platinum center.
51,168
 Activated square planar Pt(II) 
complex coordination at dG residues has been explained by an associative substitution 
mechanism (Scheme 3.1).
168
 The incoming ligand coordinates as a fifth ligand to form a 
trigonal-bipyramidal intermediate, after which the aqua ligand dissociates. The bulkier 
sugar moiety could slow down the rate-determining first step of associative substitution 
of activated compound, in which the dG residue coordinates to the Pt center.
168
 Activated 
compound 5 could have different steric and ligand-exchange characteristics compared to 
activated cisplatin, as supported by the slower reactions with both dG and G. Slower 
reaction kinetics is a desirable property in anticancer drugs because it minimizes off-
target binding.
168
 In fact, bidentate or tridentate N-donor ligands in platinum-based drugs 








Scheme 3.1. Steps of the associative substitution mechanism of a nucleophile binding 
to mono-activated cisplatin. Platinum interactions with the incoming nucleophile and 
the aqua leaving group in the trigonal bipyramidal transition state are shown.  
 
 
Between dG and G, mono-activated compound 5 is more reactive towards G. 
Compound 5 show 2.2-fold greater reactivity towards G over dG, whereas cisplatin 
display a 2-fold higher rate for dG (Table 3.1). The G nucleoside has an additional 
hydroxyl group at the 2 position of the ribose-sugar compared to dG, which could be 
involved in forming an additional hydrogen bond with the carbohydrate moiety of the 
Pt(II) compound, although this type of interaction was not verified in this thesis work. In 
an associative mechanism with a trigonal-bipyramidal transition state, the ligand cis to 
the leaving group becomes axial to the trigonal plane (Figure 3.5).
167,168
 When the 
carbohydrate group becomes axial, it has the ability to interact with the entering and 
leaving groups at an angle of 90°. Therefore, I propose that the transition state is 
stabilized by an additional hydrogen bond with the incoming G and carbohydrate moiety 











Figure 3.5. Possible trigonal-bipyramidal transition state for the mono-activated 5 
reaction with G nucleoside. The aqua ligand, adenine base, and one –NH2 of the 
carbohydrate ligand are in the trigonal plane. The other –NH2 group of the carbohydrate 
ligand and the chlorido group become axial to the trigonal plane as shown. In this 
structure, the carbohydrate group of 5 and the ribose sugar group exist above the plane, 





3.4.3 Mass analysis of products (LC-MS) 
 The mixtures of products that are generated from the reactions between G or dG 
and mono-activated 5 were analyzed by using mass spectrometry, with either LC-MS or a 
direct injection method, to identify the adducts (Chapter 2, Section 2.4.5). The m/z of all 
the possible adducts were calculated and a specific mass range (calculated m/z ± 8 Da) 
was selected in the MS for adduct identification. Both mono- and bis-substituted adducts 
were detected in the reaction mixtures after 16 h.  
Analysis of the guanosine-5 reaction mixture by LC-MS (Figure 3.6 and 3.7) 












 are 765 Da and 748 
Da, respectively. The isotopic distribution due to Pt and Cl was observed in the LC-MS 
spectra and matched the predicted spectra as shown in Figure 3.6 and 3.7. The bis-
substituted product, [Pt(C9H20O6N2)G2]
2+










 in the negative mode.
 
The retention 




,  and 
[Pt(C9H20O6N2)G2]
2+
 adducts in the LC-MS are 1.5, 4.2, and 4.3 min, respectively.  
 
Figure 3.6. The predicted and experimental mass spectra for compound 5G mono-
substituted adducts with possible structures. (a) The calculated and observed (positive 
mode) m/z for [Pt(C9H20O6N2)G(Cl)]
+
 were 765 Da. (b) The calculated mass for 
[Pt(C9H20O6N2)G(H2O)]
2+











Figure 3.7. The predicted and experimental mass spectra for compound 5G bis-
substituted adduct with possible structure. The calculated mass for 
[Pt(C9H20O6N2)2G]
2+ 





 was 1010 Da. 
 
The dG reaction mixtures were analyzed by using mass spectrometry with direct 
injection of the sample. Figure 3.8 depicts the mass spectra obtained for mono- and bis-












, 732 Da, and 981 Da, respectively. The observed peaks are similar to the 
predicted spectra in the positive mode with the masses 749 Da for 
[Pt(C9H20O6N2)dG(Cl)]
+














Figure 3.8. The predicted and experimental mass spectra for compound 5dG 
adducts with possible structures. (a) The calculated and observed (positive mode) m/z 
for [Pt(C9H20O6N2)dG(Cl)]
+
 was 749 Da. (b) The calculated mass for 
[Pt(C9H20O6N2)G(H2O)]
2+




 was observed 
(positive mode)  at 731 Da. (c) The alculated mass for [Pt(C9H20O6N2)(dG)2]
2+









In this chapter, experimental results were presented for nucleoside-mono-
activated compound 5 reactions and adduct identification. By using the nucleosides, the 
reactivity was evaluated with minimum complexity as opposed to the reactions with 
nucleic acids. The reactivity rates of mono-activated 5 were compared to that of cisplatin, 
and showed preferred binding to G over dG. However, the overall reaction kinetics were 
low for 5 compared to cisplatin, with a 2.5-fold lower rate for the reaction with G. The 
reactivity differences between mono-activated 5 and cisplatin may arise from the 
presence of different non-leaving group ligands. The lower reaction rates of mono-
activated 5 could be due to the bulkiness of the sugar moiety, which sterically hinders the 
reactivity with nucleosides. Reactivity differences of 5 compared to cisplatin could afford 
unique biological consequences such as limited off-target binding, avoiding recognition 
by repair enzymes, or altering downstream biological pathways. Further experiments 
could be carried out to explore the reactivity differences and gain new perspectives for a 















REACTIVITY OF A CARBOHYDRATE-LINKED PLATINUM COMPOUND 
WITH NUCLEIC ACIDS 
 
4.1 Abstract 
This chapter describes the reaction kinetics and structural impacts caused by 
compound 5 (cis-dichlorido[(2--D-glucopyranosidyl)propane-1,3-diammine]platinum 
(II)) at the oligonucleotide level in order to obtain some mechanistic insight into how it 
works. With the guanosine ribonucleoside binding preference of 5 as described in 
Chapter 3, it was of interest to explore the reaction kinetics at the nucleic acid level to 
mimic the cellular targets. A series of gel-based kinetic experiments was carried out, 
comparing 5 and cisplatin reactions with DNA and RNA, using both mono- and bis-
activated complexes. A salt-dependent kinetic study was also carried out to understand 
the contribution of RNA electrostatics on the reactivity of 5. The DNA structural changes 
that occur upon mono-activated compound 5 binding were evaluated by using plasmid 
and small oligomer DNAs. A reverse transcription-based primer extension technique was 
used to analyze compound 5 binding sites on ribosomal RNA (rRNA). All of these 
experiments were done in parallel with cisplatin. Compound 5 and cisplatin both formed 
platinum adducts that lead to DNA bending. Slow reaction rates were observed for 5 for 
oligonucleotides compared to cisplatin (≥3.7-fold), which was similar to the reactions 
with nucleosides. These findings reveal the impact of the carbohydrate ligand on reaction 
kinetics and target selectivity. These results agree with the fact that by changing the size 







 Certain aspects of nucleic acid interactions have been studied at great lengths to 
understand the reaction mechanism of cisplatin.
17,170,171
 DNA has long been the subject of 
intense investigation, but RNA has received more attention in recent years.
170
 These 
studies include locating the platination sites, evaluating the stabilizing (or destablizing) 
and structural effects of cisplatin on nucleic acids, kinetic measurements, understanding 




4.2.1 Kinetic studies of cisplatin-nucleic acid reactions 
 Cisplatin binding to nucleic acids is a kinetically controlled reaction.
15
 The 
chlorido ligand of cisplatin is not directly displaced by the purine base, rather it happens 
through a solvent-assisted mechanism.
172
 Therefore, the rate-limiting step in the reaction 
is the initial cisplatin hydrolysis, which is a first-order reaction.
172
 However, activated 
complexes have been used for studying the subsequent steps of platination in vitro 
without the interference from the initial rate-determining step. Kinetic studies have been 
done to get insight into the mechanism, primary reactive species, and sequence-
dependent reactivity of cisplatin with DNA.
172
 By directly using the activated complex, 
the role of the non-leaving group ligands can be elucidated as well. Sequence-dependent 
studies have identified that dGs in the context of -d(GG)- or -d(AG)- are more reactive 
towards cisplatin than other dGs, and the adduct formation is dependent on whether the 
sequence is in a single- or double-stranded region.
12,166,173
 Furthermore, flanking bases 
have been shown to play a role in platination.
174,175
 Importance of the location of the 




at the ends of an oligomer are platinated more slowly compared to those in the 
middle.
176,177
 Moreover, the intial platination step was faster at the 5'dG than at 3'dG for 
5'-d(GG)-3' target sites.
175
 Platination rates are also affected by the ions present in the 
microenvironment of the nucleic acid, as well as the pH. Higher concentrations of cations 
and increasing pH reduce the platination rates for DNA.
47,177
 Several kinetic studies for 
Pt(II)-RNA interactions have been reported.
44,48,51
 One such study showed a kinetic 
preference of cisplatin for G-C-rich and wobble base-pair regions on full-length tRNA.
44
 
A comparison between Pt(II) compound coordination to DNA and RNA revealed a more 
pronounced salt-dependent reactivity with RNA.
51
 Moreover, the effect of pH, salt, and 




4.2.2 Structural impacts of Pt(II)-nucleic acid interactions 
DNA adducts of cisplatin and some other Pt(II) complexes have been extensively 
characterized by X-ray crystallography and NMR spectroscopy.
171
 The physical effects of 
Pt(II) binding to DNA have been discussed in detail, as this has been identified as the 
main event to initiate cell apoptosis.
171
 Mainly, the effects are categorized as unwinding, 
shortening, and bending of the double-helical DNA structure.
171
 Intercalating Pt reagents 
such as [Pt(terpy)(HET)]
+ 
are known to lengthen and stiffen the DNA double helix, 
whereas cisplatin and transplatin binding shorten the DNA.
178
 Cisplatin binding to DNA 
in a bidentate fashion has a large structural impact because the complex is able to kink 
the double helix at the binding site. 
171
 With mono-functional adducts, this effect is not as 
pronounced.
179
 The DNA-bending angle for cisplatin has been quantified in several 
studies, but the values varied.
24,145,180,181




cisplatin binding to form a cis-d(GG) intrastrand cross-link on duplex oligomer bent the 
DNA about 60.
182
 By using a gel electrophoresis mobility shift assay, the cis-d(GG) 
bend angle was estimated to be about 40°.
180
 Using a similar method in another study, the 
bend angles for cis-d(GG) and cis-d(AG) adducts were 32° and 34°, respectively.
24
 In the 
case of the cis-d(GTG) 1,3 adduct, an angle of 35° was reported.
24
 A crystal structure of 
cisplatin bound to duplex DNA showed a bend angle of 26°, which is smaller than what 
was obtained from the gel and solution studies.
183
  The effect of flanking bases on DNA 
bending was evaluated in a recent study, in which the bend angles were found to be about 
32-34° regardless of what the flanking bases are at the platinated d(GG) site.
25
 
Bending causes the neighboring region to be destabilized and the Watson-Crick 
base pairing to be weakened.
171
 The neighboring bases unstack and the sugar puckering 
changes from C2'-endo to C3'-endo; thus, the standard B-DNA conformation is changed 
to A-form DNA.
171
 Changes in UV and circular dichroism spectra supported the idea of 
base unstacking within the helix.
179
 Furthermore, a decrease in melting temperature upon 
cisplatin binding revealed destabilization of the DNA structure.
179
 Alkylation at the N7 
position of purines is known to destabilize the glycosidic bond and facilitate 
depurination.
184
 However, with cisplatin binding, the glycosidic (N9-C1') linkage is 
stabilized, probably due to the better distribution of the positive charge over the Pt 
atom.
184
 Lowering the pKa of the N1 position of the purine ring from ≈ 10 to ≈ 8 upon 
platination supports this idea as well.
185
 Therefore, the anticancer activity of platinum 
compounds is often correlated with distortion of the DNA structure, which affects regular 








 In order to develop next-generation platinum anticancer drugs with less off-target 
effects, low resistance, and higher potency, it is important to understand their reactivity at 
the biomolecular level. Although clinically available platinum(II) drugs have been 
studied extensively, the biochemistry of other cisplatin derivatives is poorly understood. 
The purpose of this chapter is to evaluate the reaction kinetics of 5 with oligonucleotides, 
as well as its structural impacts on DNA and nucleotide preferences for rRNA binding to 
understand the effects of the carbohydrate ligand. 
From Chapter 3, it was clear that the kinetics are different for 5 compared to 
cisplatin at the nucleoside level, in which the overall reactivity was low for 5 and the 
guanosine ribonucleotide binding was preferred. It was of interest to evaluate the 
reactivity on DNA and RNA oligonucleotides as well as the mononucleotides. Therefore, 
the first objective of this section was to evaluate the reaction kinetics of 5 with 
oligonucleotides to compare their binding preferences, and to gain insights into the basis 
of these differences. Kinetic studies with mono- and bis-activated compound 5 were done 
to compare the reaction rates with DNA and RNA oligonucleotides. Salt-dependent 
kinetic rates were also obtained for the reaction between mono-activated 5 with DNA and 
RNA to understand the electrostatic contributions on the reactivity. Similar experiments 
were carried out with cisplatin for comparison.  
After establishing the reactivity with oligonucleotides, the next question to ask 
was what is the impact of binding on the nucleic acid structure? If a potentially active 
molecule does not distort the nucleic acid structure or inhibit a nucleic acid-related 
functions, its activity may not be the result of targeting nucleic acids.
171




second objective of this study was to determine the structural changes caused by mono-
activated 5 on DNA in comparison to cisplatin.  
Previous studies showed that cisplatin’s anticancer activity correlates with DNA 
binding. However, with more mechanistic studies available, this idea has been challenged 
and cisplatin has been shown to bind to other cellular targets such as RNA and 
proteins.
39,186,187
 In particular, cellular RNA has received some attention in recent 
years.
187
 Considering the abundance, accessibility, and functional importance, rRNA can 
be considered as one of the potential targets of Pt(II) compounds.
187
 Furthermore, the 
biologically active compound 5 showed higher reactivity towards the guanosine 
ribonucleoside compared to the corresponding deoxy nucleoside. Therefore, the third 
objective was to evaluate the nucleotide preferences of 5 binding to rRNA. The effects of 
the carbohydrate ligand on structural and kinetic properties are clues in understanding the 
biological activities of glycoconjugated molecules. Overall, this chapter aims to provide 
information about steric, electronic, and hydrogen-bonding properties of compound 5 that 
influence nucleic acid binding and kinetics of the molecule. 
4.4 Results and discussion 
4.4.1 Kinetic studies for mono-activated 5 and nucleic acid reactions  
 Kinetics are crucial to the antitumor properties of a drug. Chapter 3 evaluates the 
binding kinetics with the building blocks of nucleic acids in a simplified environment. 
However, it is important to compare these data to kinetic parameters of nucleic acids to 
get a better view of the activity of platinum compounds. More complex secondary and 
tertiary structures of nucleic acids, cations and solvents in the microenvironment, and 




determine the drug-nucleic acid interactions.
188
 Kinetic, thermodynamic, and structural 
preferences of the drug are governed by these parameters.
188
 
The DNA and RNA strands used for my kinetic experiments are similar in length 
(22-mer), sequence (except for T in DNA and U in RNA), and have only one -GG- site 
for platination (DNA1 and RNA1). The single-stranded nucleic acids were radiolabeled 
at the 5 end for visualization during gel electrophoresis. The first hydrolysis of cisplatin 
is the rate-limiting step. Therefore, by using mono-activated platinum complexes, factors 
influencing the direct coordination step could be rapidly evaluated without interference 
from the first hydrolysis. Under excess Pt(II) concentration, this reaction was expected to 
obey pseudo-first-order conditions. The pseudo-first-order rate constant, kobs, for the 
reaction between different concentrations of mono-activated 5 and DNA were obtained as 
described in Chapter 2, Section 2.4.9. The Pt(II) compound was maintained at a 134-
fold higher concentration than that of the oligonucleotide. This condition maintained the 
pseudo-first-order rate. Specifically, the final concentration of the added mono-activated 
Pt(II) complex was 94 μM. This procedure was repeated with RNA for direct 
comparison. The experiment was also carried out with mono-activated cisplatin to 
compare the rates to those of the carbohydrate complex.  
Results obtained with DNA are shown in Figure 4.1 and the results obtained with 
RNA are shown in Figure 4.2. As shown in Figure 4.1a and b, addition of mono-
activated 5 and cisplatin to nucleic acids results in a decrease of unplatinated nucleic acid 
in a time-dependent manner as observed on denaturing polyacrylamide gel images. 
Slower migrating product bands are observed on the gels. The fraction of unreacted 




2.4) to obtain the kobs. Standard errors were calculated from three independent 
experiments.  
 
Figure 4.1. Representative results for the kinetic experiment between DNA and 
mono-activated Pt(II) complexes. The gel images for the reactions between DNA with 
mono-activated (a) compound 5 and (b) cisplatin showed the time-dependent decay of 
unreacted DNA and formation of the products ([DNA] = 0.7 μM, [Pt(II)] = 94 μM; 10 
mM K2HPO4/KH2PO4, pH 6.2, with 20 mM NaClO4, 37 °C). The fraction of unreacted 
DNA over time for the mono-activated (C) compound 5 and (d) cisplatin showed 







Figure 4.2. Representative results for the kinetic experiment between RNA and 
mono-activated Pt(II) complexes. The gel images for the reactions between RNA with 
mono-activated (a) compound 5 and (b) cisplatin showed the time-dependent decay of 
unreacted RNA and formation of the products ([RNA] = 0.7 μM, [Pt(II)] = 94 μM; 10 
mM K2HPO4/KH2PO4, pH 6.2, with 20 mM NaClO4, 37 °C). The fraction of unreacted 
RNA over time for the mono-activated (c) compound 5 and (d) cisplatin showed 
exponential decay.  
 
For the reaction of mono-activated compound 5 with DNA, the rate is 14-fold 
lower than that of cisplatin (Table 4.1). For RNA, the rate is 3.7-fold lower. Therefore, 
mono-activated 5 shows slower reactivity with oligonucleotides compared to cisplatin, 
similar to the reactions with nucleosides in Chapter 3. This difference could be due to 
the steric hindrance caused by the larger carbohydrate group of 5 when approaching the 
target site because the carbohydrate group is in the axial position of the six-membered 
chelate ring.
161
 Furthermore, the six-membered ring between the Pt and the carbohydrate 




during the coordination reaction. That difference could cause slower reactivity of mono-
activated 5. This effect is also observed for carboplatin, in which the bidentate leaving 
group ligand accommodates a boat configuration, which blocks reactions with the 
incoming nucleophiles.
189
 Moreover, the Pt(II)-based anticancer compound picoline has 
also shown reduced reactivity due to steric effects caused by the non-leaving group 
ligand compared to cisplatin.
190
 This characteristic has been considered beneficial in 




Table 4.1. Pseudo-first-order rate constants, kobs for the reactions of mono-activated 



















DNA 7.4 ± 0.8 0.54 ± 0.05 
RNA 3.3 ± 0.7 0.9 ± 0.1 
 
As shown in Table 4.1, mono-activated cisplatin shows a 2.2-fold preference for 
DNA over RNA, whereas 5 shows a 1.7-fold preference for RNA. Therefore, the RNA 
preference of mono-activated compound 5 is also present at the oligonucleotide level, 
similar to the nucleosides. The geometric environment of the DNA and RNA might 
influence electrostatics of the nucleic acids, and subsequently the kinetics of Pt(II) 
interactions. The RNA structure creates multiple electrostatic pockets for metal 
binding.
192
 In biology, Mg
2+
 is associated with the RNA regions to modulate electrostatic 
potentials.
127
 In contrast to DNA, RNA adopts an A-form structure and the major groove 
is shown to be more electronegative than the minor groove.
192,193
 This property may 




derived small molecules such as aminoglycosides preferably target RNA based on 
hydrogen-bonding capabilities of the drug.
122
 Therefore, specific hydrogen-bonding 
interactions between the multiple sugar –OH groups of the carbohydrate ligand and RNA 
could be one of the reasons that the mono-activated 5 has preferred reactivity towards 
RNA compared to cisplatin.  
4.4.2 Kinetic studies for bis-activated 5 and nucleic acid reactions  
 
 There could be various reasons for the observed low coordination rates of mono-
activated compound 5 with DNA and RNA compared to cisplatin. The experiments were 
carried out with mono-activated Pt(II) compounds; therefore, the effect of the rate-




) is not the reason for slow coordination.
16
 
The mono-activated compound can react with nucleosides or undergo second hydrolysis 
to produce the bis-activated complex. These competing reactions may impact the 
observed slow rates for the mono-activated compound 5. Therefore, by using bis-
activated compounds, we could analyze the effect of the structure or role of the overall 
charge of the complex (+1 vs. +2) on the reaction rate. As shown in Table 4.2 and 
Appendix B-Figure A1, the experiment was carried out with both DNA and RNA.  
Table 4.2. Pseudo-first-order rate constants, kobs for the reactions of bis-activated 



















DNA 17 ± 2.7 0.2 ± 0.09 
RNA 5.2 ± 1.6 0.3 ± 0.05 
 
The same reactivity patterns are observed, similar to the mono-activated cisplatin, in 




the bis-activated cisplatin. For bis-activated 5, a significant difference between the rates 
for DNA and RNA is not observed. 
 
Figure 4.3. Comparison of reaction rates obtained from DNA and RNA with mono- 
and bis-activated Pt(II) complexes. The rate comparisons for (a) cisplatin and (b) 
compound 5 are shown. The errors were calculated from three independent experiments. 
 
The obtained rates for mono- and bis-activated form of each compound are 
compared and summarized in Figure 4.3. Higher reaction rates for the bis-activated 
cisplatin (compared to mono-activated) are observed for both DNA and RNA.
167,194
 This 
result also agrees with previously reported data, in which bis-activated cisplatin had a 
higher reaction rate than the mono-activated complex with DNA.
174,194
 There are a few 
explanations to the observed higher rates for the bis-activated cisplatin. Compared to the 
monocation, the dication would facilitate the compound to be attracted more towards 
polyanionic nucleic acids and therefore increase the reaction rate. Moreover, the oxygen 
on the aqua ligand is less electronegative compared to the chlorido ligand, which would 
strengthen a hydrogen bond between the –NH3 ligand and O6 of the guanine base. This 
interaction would increase the reaction rate of bis-activated cisplatin by stabilizing the 
transition state and decreasing the activation energy. In contrast, bis-activated 5 show a 3-




effect may be due to the larger carbohydrate non-leaving group near the Pt(II) reactive 
center as explained in the Section 4.4.1 (so charge effect is reduced due to steric bulk).  
4.4.3. Salt-dependent kinetic studies of 5 with nucleic acids 
 Coordination reactions between activated Pt(II) complexes with nucleic acids 
occur in two steps.
195
 In the first step, the Pt(II) compound associates with DNA or RNA 
by displacing a fraction of surface-bound cations. The second step is direct coordination 
to the target. Activated-Pt(II) complexes are positively charged; therefore, the first 
association step is affected by cations in the media. Therefore, a salt-dependent kinetic 
study was carried out with mono-activated 5 in comparison to cisplatin with DNA and 
RNA to evaluate the contribution of electrostatics on the reaction. The platination rates 
were obtained from reactions in two buffer conditions, in which both had 12 mM K
+
. 
Additionally, one condition was 5 mM Na
+
, whereas the other was 20 mM Na
+
. The 
comparative results are shown in Table 4.3, Figure 4.4, and Appendix A-Figure A3.  
Table 4.3. Pseudo-first-order rate constants, kobs for the reactions of mono-activated 

































DNA 24 ± 5 2 ± 0.4 12 




DNA 7.4 ± 0.8 0.54 ± 0.05 13.7 
RNA 3.3 ± 0.7 0.9 ± 0.1 3.7 
 
At the low salt concentration (5 mM Na
+
), the reaction rate differences between 




the high salt concentration (20 mM Na
+
), mono-activated cisplatin shows a 2.2-fold 
preference for DNA over RNA, whereas 5 shows a 1.7-fold preference for RNA. This 
shows that the target preference can vary depending on the cations in the environment.
51
 
With increasing salt, the reaction rates decrease for both mono-activated cisplatin and 5, 
likely due to increased competition for binding to the target. This result agrees with 
previous reports.
50
 With DNA, both mono-activated compounds show a decline in the 
reactivity with increasing salt concentration (3.2-fold for cisplatin and 3.7-fold for 5, 
respectively). A more pronounced salt effect was observed for the RNA and mono-
activated cisplatin reaction (10-fold) in the two buffer conditions. However, only a 1.5-
fold rate difference was observed for the reaction with mono-activated 5 and RNA at the 
two buffer conditions, suggesting that electrostatics play a less significant role in RNA-5 
interactions.  
 
Figure 4.4. Comparison of salt-dependent reaction rates obtained for mono-
activated (a) cisplatin and (b) compound 5 with DNA and RNA. The errors were 
calculated from three independent experiments. 
 
Taken together, these kinetic data suggest that compound 5 has a slight preference 
for RNA over DNA. The size of the molecule may also play a role in governing the 
reaction. These results agree with previous studies, in which it was shown that large 






 These observations may influence the design of new carbohydrate-Pt(II) 
drugs that have reduced off-target binding. Additionally, compound 5 may favor RNA 
binding and therefore, future studies can be done to evaluate the reactivity of 5 with 
RNA.  
4.4.4 Structural impacts of mono-activated 5 on plasmid DNA 
Early studies with cisplatin and transplatin were done with plasmid DNA.
178
 
Plasmid DNA is topologically constrained, so that if there are any alterations causing 
changes in the number of helical turns, that effect is reflected on the DNA 
superhelicity.
178
 Unwinding can be deduced by the changes in the superhelicity, which 
can be monitored by gel electrophoresis. Initial experiments to evaluate the structural 
effects of mono-activated 5 were carried out with pUC19 plasmid and compared to 
results with mono-activated cisplatin. Mono-activated 5 or cisplatin (160 μM each) were 
incubated with plasmid (0.5 μg) for different time periods as described in Chapter 2, 
Section 2.4.11. The reactions were quenched and analyzed on agarose gels (Figure 4.5). 
Figure 4.5. The gel images of the plasmid DNAs platinated by mono-activated (a) 
cisplatin and b) compound 5. ([DNA] = 0.5 μg, [Pt(II)] = 160 μM; 10 mM 
Na2HPO4/NaH2PO4, pH 7.4, 37 °C). The reactions were quenched at the time points 
indicated at the bottom of the images. The cartoon figures on the right show the 
topological forms of the closed circular DNA. 
 
The bands corresponding to the supercoiled plasmid DNA exhibit different gel 




cisplatin or compound 5. The differing gel migration distances are caused by bending and 
unwinding of the plasmid DNA induced by the platinum adduct. The supercoiled plasmid 
platinated by mono-activated Pt(II) complexes becomes more relaxed, decreasing the 
electrophoretic mobility of the DNA. Upon further incubation with mono-activated 
cisplatin, relaxed plasmid DNA appears to rewind in the opposite direction to be 
supercoiled (30 min- 24 h time period). In contrast, the supercoiled region of plasmid 
platinated by mono-activated compound 5 is only seem to become more relaxed during 
the same incubation period. This suggests that compound 5 has a kinetically slower effect 
on the DNA plasmid structure than cisplatin. 
4.4.5 Structural impacts of 5 on short duplex DNA oligomer 
While the reactions with plasmid DNA allowed us to investigate more of the 
global structural changes, a DNA bending study was carried out with a short DNA duplex 
with a single -d(GG)- site as described in Chapter 2, Section 2.4.12 to understand the 
structural impact at the local binding site. Depending on the binding mode the effect on 
the secondary structure can vary. A gel electrophoresis mobility shift assay that was 
reported in the literature for quantifying the DNA-bending angle was utilized in this 
study to evaluate the effect of 5.
24
 This method was developed based on a previous 
method that was used to study DNA bending at naturally occurring d(A5T5)2 sequences 
known as A-tracts.
196
 Presence of this sequence in the center of a DNA leads to bending 
of the DNA structure, thereby causing reduced mobility in a gel. Moreover, it has been 
shown that if there are multiple A-tracts in a DNA, the bends will be phased 
constructively if they are located ~10.5 helical turns apart.
145,196
 Other spacings caused 




Pt bending studies was designed keeping the above facts in mind, in particular the 
spacing of the d(GG) site. 
My experiments were carried out with a 22-base pair DNA duplex molecule 
(Scheme 4.1) that was used previously with cisplatin (top and bottom strands are referred 
to as DNA1 and DNA2).
24,144 
The sequences were designed to have a two-nucleotide 
overhang on each end to facilitate ligation in only one orientation. DNA1 has a 5' 
phosphate and a single -d(GG)- site for platinum coordination. DNA2 is complementary 




Scheme 4.1. Sequences of DNA used in the bending experiments. 
DNA1:            5' p-TCT CCT TCT TGG TTC TCT TC TC-OH 3'  
DNA2: 3' HO-AG AGA GGA AGA ACC AAG AGA AG-OH 5' 
 
To facilitate the efficient platination of DNA1, it was reacted with a 1:2 ratio 
(DNA:Pt) of bis-aquated Pt(II) complexes (Figure 4.6a). The MALDI-MS spectra 
confirmed single platination of DNA1 in the gel-purified product (Figure 4.6b and c). 
The mass of DNA1 was calculated to be 6,640 Da and after coordination to cisplatin, the 
mass of the DNA1-Pt product was 6,868 Da, which corresponds to single platination 
most likely at the –d(GG)- site. For 5 coordinated to DNA1, the mass was 7086 Da with a 






Figure 4.6. The platination of DNA1. (a) The DNA1 sequence with a single platination 
site and MALDI-MS spectra for the reaction of DNA with (b) cisplatin and (b) compound 
5 are shown. The spectra were obtained in positive-ion reflector mode (3-HPA matrix). 
The calculated mass of the single-stranded DNA (M) is 6640 Da. The masses of the 
DNA1-Pt products correspond to bidentate coordination for a single adduct ([DNA1-
Pt(NH3)2]
+/2+
 for cisplatin and [DNA1-Pt(C9H20O6N2)
+/2+
 for compound 5). 
 
Initial experiments were carried out with cisplatin to verify the DNA bending 
method and compare to published data.
24
 The platinated and unplatinated DNA1 strands 
were annealed and ligated with bottom strand (DNA2) in separate reactions. The effects 
of platination on the DNA structure were determined by analyzing the reaction mixtures 
on 8% native polyacrylamide gels. The ligation of duplex monomers leads to the 
formation of DNA oligomers. Initially, different ligation times were tested. Figure 4.7a 
shows the results for one and 16 h ligations. Both conditions show the same results of 




Figure 4.7. Results for DNA bending caused by cisplatin. (a) The 8% native 
polyacrylamide gel image for DNA bending experiments with and without cisplatin is 
shown. (L= linear ligated DNA oligomers, C= circular ligated DNA oligomers; the 
numbers 2, 3, 4, etc.  correspond to the number of duplex monomers that are ligated 
together. Lanes 5-7 contain reaction mixtures treated with thiourea to remove the Pt 
adduct. Reactions 8-10 are controls (separate gel). (b) A schematic diagram of the DNA 
ligation with and without cisplatin, and (c) the calibration curve constructed for the (-) 
cisplatin DNA are shown. 
 
In the reaction with unplatinated DNA1, the duplex monomers were expected to 
ligate to give linear oligomers, which is indeed observed in Figure 4.7a (for example, L4 
represents a linear oligomer with four monomers ligated together). In contrast, the 
platinated DNA has a reduced mobility on the gel as seen in Figure 4.7a. We believe this 
effect is due to the bending effect of the cisplatin adduct on the DNA structure (Figure 
4.7b). For the platinated DNA, migration retardation is observed particularly for the 




distance of the ligated DNAs due to curvature introduced by the platinum adducts.
24
 The 
chosen DNA sequence predicts the bends to be spaced evenly, such that constructive 
addition of bends leads to circular DNA. With an increasing number of bends that are 





 the circularization occurs when five double-stranded 
monomers are ligated together (C5-110 bp) and the resulting circle comigrates with L6.   
As reported by Bellon and Lippard, the difference in the migration of the 
platinated DNA relative to the unplatinated DNA can be used to quantify the bend angle 
caused by cisplatin.
145,197
The migration distances of the bands on the gel corresponding to 
unplatinated DNA (lanes 1 and 3) were measured manually and a calibration curve was 
constructed between the log size of the DNA and migrated distance (Figure 4.7c). From 
the plot, the calculated length for a particular linear platinated DNA can be obtained. The 
calculated length is based on an oligomer’s mobility. Using the equation obtained from 
the calibration curve (y = -0.0947x + 3.038), the calculated lengths (y) were determined, 
in which x is the migration distance for the linear platinated DNA (Table 4.4). 
















L2 14.9 1.63 42 44 0.95 
L3 12.5 1.85 71 66 1.1 
L4 11.0 1.99 99 88 1.1 
L5 8.6 2.22 167 110 1.5 
 
The relative mobility (RL) of the platinated DNA is the ratio between the 




calculated length and actual length, the RL is 1 for all points. With higher curvature in the 
DNA structure, mobility retardation is higher and results in higher RL values. As shown 
in Table 4.4, the platinated DNA has RL>1 for longer oligomers (≥L3). Determination of 
the DNA bend angle caused by cisplatin is performed using Equation 4.1, in which L 
represents the length of a particular oligomer with relative mobility RL and RC is the 
curvature relative to DNA bending of an A tract (A DNA with a known bend 
angle).
24,144,145
 Application of Equation 4.1 to the 110-bp multimer composed of the 22-
bp platinated monomers gives a curvature of 0.85. To determine the average bend angle 
in degrees, the RC value is multiplied by the absolute value of two A6 tract (40°).
197,198 
The result predicts the bend induced by the cisplatin 1,2-d(GG) intrastrand crosslink to be 
34°, which corresponds well with previous studies.
24
 The experiment was repeated three 
times and the bending angle was calculated using the 110-mer to be 34 ± 1°.  






                          Equation 4.1 
After establishing the protocol with cisplatin, the same experiment was carried out 
with DNA platinated by bis-activated compound 5 (Figure 4.8). Similar bands are 
observed with reduced mobility, together with bands corresponding to circular products. 
The band corresponding to linear 5-mer, which is used for quantification, is more 
prominent in cisplatin than for compound 5, which suggests the rate of cyclization could 
be different for the two compounds. Therefore, the 6-mer (132 bp) band was used to 
quantify the bend angle for compound 5. The band migration distances were measured 
and the DNA-bending angle was computed to be 36 ± 1° (two trials), which is similar to 





Figure 4.8. Results for DNA bending caused by 5. (a) The 8% native polyacrylamide 
gel image for DNA bending experiments with and without compound 5 is shown. (L= 
linear ligated DNA oligomers, C= circular ligated DNA oligomers; the numbers 2, 3, 4, 
etc.  correspond to the number of duplex monomers that are ligated together. Lanes 3 and 
4 are reactions treated with thiourea to remove the Pt adduct. (b) The calibration curve 
constructed for the (-) Pt DNA is shown. 
 
To show that the mobility change is due to platinum adduct formation, saturated 
thiourea was used to reverse the platination.
199
 When the ligation products modified with 
cisplatin and 5 were incubated with saturated thiourea (0.2, 0.5, or 1 μL) for 72 h at 37 °C 
(lanes 5-7 in Figure 4.7 and lanes 3-4 in Figure 4.8), the linear platinated DNA bands 
show similar migration patterns as the unplatinated DNA (lane 1). Even after removing 
the Pt, the upper bands (corresponding to C5-C8)) in the gel have slower mobility, 




circular products is evidence for the ability of 5 to significantly bend the DNA structure 
so that the ends will come closer together for ligation. 
Figure 4.9 shows crystal structures of cisplatin and oxaliplatin bound DNA, in 
which the adducts are located in the major groove of DNA.
181,200
 The crystal structures 
consist of a DNA dodecamer duplex with a sequence of 5-CCTCTGGTCTCC.
181,200
 
There is only one platination site in the middle of the sequence. Irrespective of the length, 
this DNA duplex is very similar to the one used in my study. Thus, it is a good 
representation of the platinum adducts bound to duplex DNA. Compound 5 adduct was 
modeled onto the crystal structure of oxaliplatin to represent the binding. Although the 
positioning of the sugar pendent may slightly vary in an actual structure, this model 
structure gives an indication of how compound 5 sits in the major groove of a DNA 
duplex. The adduct of 5 is bulkier than cisplatin and oxaliplatin, and it likely sits in the 
DNA pocket with the sugar group protruded outside, similar to oxaliplatin.  
Figure 4.9. Crystal structures of Pt(II) complex-bound DNA duplex. The DNA 
dodecamer duplex has a single GG-site for platination with (a) cisplatin (PDB: 1AIO), (b) 
oxaliplatin (PDB: 1IHH) and (c) compound 5.
181,200
 The other nucleotides in the duplex 
are C and T. Platinum atom is shown is dark blue color and the chemical structure of the 
Pt(II) complex is shown below each crystal structure. The crystal structure for 5 was 
modeled based on the oxaliplatin-DNA structure. 
 
























Depending on the Pt(II) adduct, the effect on DNA structure varies. For example, 
monofunctional or intercalating adducts unwind DNA, whereas cis intra- and interstrand 
bifunctional adducts unwind and bend the DNA.
201
 Moreover, trans-1,3-intrastrand 
adducts cause the middle nucleotide to bulge out.
171
 Furthermore, trans adducts cause a 
hinge joint at the locus, which does not lead to cooperative bending. Previous studies 
showed that the formation of 1,2-d(GG) instrastrand cross-links by cisplatin leads to 
DNA bending towards the major groove and unwinding of the DNA.
183
 Taken together, 
my results support the hypothesis that compound 5 makes a 1,2-d(GG) intrastrand cross-
link with DNA that leads to DNA bending as well. Appearance of similar circular bands 
for cisplatin and compound 5 further suggests similar DNA bending caused by platination 
on duplex DNA. The calculated bend angles are in the same range as previously reported 
bend angles from similar gel-based assays (32-40°). In fact, additional hydrogen-bonding 
interactions of 5 could further restrain the DNA duplex and orient it for faster ligation 
than cisplatin. Such interactions has been shown with oxaliplatin where additional 
hydrogen-bonding interactions are present between the NH of the (R, R)-DACH ligand 
and the O6 atom of the 3′-dG of the d(GG) lesion.
200
 The search for a better anticancer 
drug might include molecules that can form hydrogen bonds directly to DNA in the 
vicinity of the lesion, similar to oxaliplatin. Therefore, it may be promising to use 
compounds related to 5 that have similar hydrogen-bonding properties. The toxicity of 
cisplatin comes from these lesions on DNA; therefore, it was of interest to compare the 





4.4.6 Evaluation of structural and sequence specificity of mono-activated 5 by 
probing ribosomal RNA 
 The size and charge of the non-leaving group ligands can affect the binding 
selectivity to oligonucleotides. With previous experiments, compound 5 binding to d(GG) 
sites of DNA has been shown. With the observed kinetic preference of mono-activated 
compound 5 for RNA over DNA, it was of interest to further explore the RNA binding 
aspects of compound 5. Amino-sugar derived drugs are largely known to interact with 
RNA,
120
 specifically rRNA, due to their capability of hydrogen bonding with the target. 
Furthermore, the ribosome has specific binding pockets to accommodate different ligands 
as a part of its normal biological role.
97
 The ribosome is a ribonucleoprotein complex that 
plays a significant role in the protein translation process.
97
 The ribosome is a highly 
abundant, complex structure that is a common drug target.
97
 With the similarity between 
DNA and RNA purine nucleotides, the ribosome and other functionally important RNAs 
can be secondary targets for platinum drugs. There have been previous efforts to study 
cisplatin binding to RNA. These studies have included probing of rRNA to identify 
platination sites,
43
 localization studies to show where cisplatin is accumulating in the 
cell,
46
 and kinetic studies to determine the rates of RNA platination.
51
 A crystal structure 
of the T. Thermophilus 70S ribosome modified with cisplatin is also available.
40
 In this 
study, structural and sequence specificity of mono-activated compound 5 binding to 
rRNA was evaluated in the context of the ribosome. The method is included in Chapter 
2, Section 2.4.13-2.4.15 (this work was done in collaboration with Dr. Nisansala 
Muthunayake). Considering the bulky sugar ligand of 5 compared to the simple ammines 




Certain regions in the ribosome are critical for its biological function, namely 
translation. Based on a recently published cisplatin-bound ribosome crystal structure,
40
 
h24 (790 loop), h44, h43, and the peptidyltransferase center (PTC) were chosen to map 
the binding sites of mono-activated 5 on the rRNA. Additionally, H69 has been 
extensively studied as a cisplatin-binding site in our lab; therefore, it was of interest to 
probe H69 as well. Out of the probed functionally important rRNA regions, h24, h44, and 
h43 are located in the small subunit of the ribosome, whereas the PTC region and H69 
are located in the large subunit. The DNA primers were designed to anneal to 
complementary regions of RNA, upstream of the site of interest. For example, the 
radiolabeled primer for the 790 region anneals at positions 831-814 of 16S rRNA (E. coli 
numbering) and extends towards the 790 region during reverse transcription. The 
platinum-modified nucleotide locations can be detected by reverse transcriptase stops on 
the 3' side of the adduct. There are some stop sites visible in the control lane due to RNA 
secondary structures that block reverse transcriptase. Dideoxy sequencing was done in 
parallel to compare with the reverse transcription reactions. Band intensities at the stop 
sites were quantified and normalized to standard bands to achieve the % reactivity. The 
bands with ≥50% were considered as major stop sites, whereas the ones below 50% were 
considered as minor sites. 
Figure 4.10 shows the result for probing the 790 loop, which is part of helix 24 
(h24) in the small subunit, with mono-activated cisplatin and 5.
202
 There is a prominent 
stop site at U801 for cisplatin, which is consistent with previously published data from 
our lab.
43
 As shown in the secondary structure map, this site is in the internal loop region 




observed at A792, A777, and C770, and a minor stop site at C795 for cisplatin, where all 
residues are located 3' to purine reactive sites. Minor stop sites are observed for 5 at all of 
the above-mentioned residues. Nucleotides A792, A777, and C770 are proposed to 
participate in adduct formation with neighboring G residues, similar to cisplatin. In 
contrast, the stop at C795 suggests adduct formation at the adjacent A residue. 
 
Figure 4.10. Probing result for ribosomal h24 (790 loop) region with mono-activated 
cisplatin and 5. (a)The autoradiogram shows reverse transcription mapping of in vitro 
reactive sites of mono-activated cisplatin and 5 on 70S ribosomes in a 1:200 molar ratio. 
The stop sites for cisplatin () and 5 () are shown with symbols (
,major, 
,minor 
adduct). Dideoxy sequencing lanes are labeled as U, C, A, and G. (b) The rRNA 
secondary structure with the corresponding platinum-reactive sites is shown. The primer 
binding site is shown with an arrow. 
 
The 790 loop is located near the ribosome decoding site. Chemical and enzymatic 
probing, as well as mutagenesis and structure studies, have revealed this region to be 




well as playing a key role in translation initiation.
203
 Notably, the Pt(II) modification site 
at A790 and G791 is at the mRNA channel, where the rRNA directly contacts the bound 
mRNA.
40
 Cisplatin has been shown to coordinate to A790 and mRNA in a recent x-ray 
structure, and therefore may prevent mRNA translocation.
40
 Furthermore, Pt(II) binding 
at A794 could affect P-site binding of tRNA, similar to the antibiotic edeine.
103
 
Therefore, platination at these positions could potentially prevent protein synthesis. 
Figure 4.11. Probing result for ribosomal h44 (A site) and h43 regions with mono-
activated cisplatin and 5. (a) The autoradiogram shows reverse transcription mapping of 
in vitro reactive sites of mono-activated cisplatin and 5 on 70S ribosomes in a 1:200 
molar ratio. The stop sites for cisplatin () and 5 () are shown with symbols 
(
,major, 
,minor adduct). Dideoxy sequencing lanes are labeled as U, C, A, and G. 
(b) The rRNA secondary structure with the corresponding platinum-reactive sites is 
shown. The primer binding site is shown with an arrow. 
 
 The ribosomal decoding site (A site) is in h44 of 16S rRNA, and it is involved in 
maintaining translation fidelity.
103




A site (e.g., neomycin and kanamycin) or regions near A site (hygromycin B) and thereby 
prevent the translocation of mRNA and tRNA on the ribosome.
204
 Cisplatin and 5 show 
multiple coordination sites between the A1415 and G1423 region, which has many 
wobble pairs (Figure 4.11). A strong 5 binding site is located at G1334, next to a wobble 
pair and another minor binding is detected at G1370 of the h43 region. 
 
Figure 4.12. Probing result for the ribosomal H69 region with mono-activated 
cisplatin and 5. (a)The autoradiogram shows reverse transcription mapping of in vitro 
reactive sites of mono-activated cisplatin and 5 on 70S ribosomes in a 1:200 molar ratio. 
The stop sites for cisplatin () and 5 () are shown with symbols (
,major, 
,minor 
adduct). Dideoxy sequencing lanes are labeled as U, C, A, and G. (b) The rRNA 
secondary structure with the corresponding platinum-reactive sites is shown. The primer 
binding site is shown with an arrow. 
 
 Mono-activated compound 5 binding to H69 region of the 23S rRNA is observed 
as shown in Figure 4.12. Platination is observed for both cisplatin and 5 at G1921-22 
residues, which are next to a wobble pair. In vitro studies with model H69 hairpin loop 
have confirmed the cisplatin binding at G1921 and G1922 as well.
95
 H69 region forms 
the intersubunit bridge B2a with h44 in the 70S ribosome.
205
 This region undergoes 






Therefore, it is likely that Pt(II) drug binding to these dynamic motifs could inhibit 
protein translation.  
 
Figure 4.13. Probing result for ribosomal PTC region with mono-activated cisplatin 
and 5. (a)The autoradiogram shows reverse transcription mapping of in vitro reactive 
sites of mono-activated cisplatin and 5 on 70S ribosomes in a 1:200 molar ratio. The stop 
sites for cisplatin () and 5 () are shown with symbols (
,major, 
,minor adduct). 
Dideoxy sequencing lanes are labeled as U, C, A, and G. (b) The rRNA secondary 
structure with the corresponding platinum-reactive sites is shown. The primer binding site 
is shown with an arrow. 
 
The PTC region of the 23S large subunit of the ribosome is another targeted 
region for multiple drugs. My probing results reveal cisplatin binding sites at the PTC 
region, but none for 5 (Figure 4.13). Similar to the published crystal structure with the 
platinum-modified ribosome, strong stop sites at the A2530-G2535 region suggest 
cisplatin binding. This region interacts with the ribosomal protein L6, and therefore, the 
C-terminus of the protein is likely to interact with the Pt adduct.
40
 These contacts at the 






drugs such as macrolides and peptides are known to bind to the upper exit channel of the 
PTC region.
207
 Preliminary probing data show interactions at A2058-2059, which are 
residues in the macrolide binding pocket (data not shown).
207
  
The sequence preference for cisplatin binding to DNA is well characterized. 
Cisplatin prefers binding to G-C rich DNA sequences. The adducts mostly form at –
d(GG)- or –d(AG)- sequences.
166
 Furthermore, the flanking bases also play a role in 
platination.
174,175
 The main factor governing the structural specificity of cisplatin is 
accessibility of the N7 of guanine base for reactions with aquated cisplatin. One study 
with a DNA hairpin, d(CGCGTTGTTCGCG) showed that guanine located in the loop is 
preferred for reactivity over guanines in the stem region due to the increased solvent 
accessibility.
47
 Some of the types of adducts formed in RNA are similar to DNA.
43,208
 
Reactivity studies with RNA have also shown cisplatin binding at loop regions, A 
residues, G-C-rich, and wobble base-pair regions using full-length tRNA and ribosomal 
RNA.
44,208
 The reactive sites observed in my probing studies showed similar trends as 
with the above-mentioned sequences and secondary structures. The adducts occur at 
purine residues in the context of –d(GG)- or –d(AG)- sequences. Furthermore, we 
observed that Pt(II) compounds seem to prefer binding to non-standard duplex regions, 
such as mismatches. Only a few adducts were located at the residues involved in 
canonical base pairing with a standard A-form helix. All other sites were involved with 
bulges, internal loops, hairpin loops, or GU wobble pairs. Interestingly, many of the 
major binding sites of mono-activated 5 were at or next to wobble pairs. Wobble pairs 
have been implicated in RNA functioning in some studies.
127
 The GU wobble pair is the 
most common non-Watson-Crick pair in RNA.
209




major groove of RNA have more negative surface potentials, which may play a role in 
metal binding.
209,210
 In the rRNA probing, some of the positively charged cisplatin and 5 
binding sites were at GU wobble pair sites, probably due to the high negative potential 
at those sites.  
My results suggest that cisplatin and 5 have some similar reactive sites. But compared 
to cisplatin, 5 showed overall lower band intensities at the reactive sites. Irrespective of 
the bulky carbohydrate ligand of 5, it is noteworthy to observe 5 reactivity at most of the 
cisplatin reactive sites. This agrees with the RNA preference of mono-activated 5 and 
implies that sugar conjugation has altered the target specificity of the platinum 
compound. 
Overall, the data in this chapter shows the reactivity of compound 5 compared to 
cisplatin. The two compounds have different non-leaving group ligands, and by 
comparing similarly activated compounds side by side, we could evaluate the role of the 
ligands on the activity. My data show that carbohydrate conjugation reduces the reaction 
rates of compound 5 relative to the parent cisplatin, likely due to steric effects and 
restricted flexibility of the carbohydrate moiety. These key structural differences in the 
compound may help minimize off-target binding. The DNA structural changes caused by 
compound 5 binding were also analyzed by using plasmid and short oligomer DNAs. 
Compound 5 caused unwinding and bending of the DNA, similar to cisplatin, even 
though the binding event appeared to be slower than cisplatin. Kinetic studies of mono-
activated compound 5 showed preference towards RNA over DNA. Furthermore, 
ribosome-binding studies showed that the compound 5 binding sites overlap with 




potentially disrupt the protein translation process. Therefore, further efforts towards the 
design of carbohydrate-linked platinum analogs for the treatment of specific cancers 














































POTENCY AND ACCUMULATION OF A CARBOHYDRATE-LINKED 
PLATINUM COMPOUND IN HUMAN CELL LINES 
 
5.1 Abstract   
Different platinum anticancer drugs have different levels of potency in different 
cancer types. To explore the cytotoxicity of the carbohydrate-platinum compound (5) 
towards various cancer cell lines, a series of MTT assays were carried out. Comparable 
cytotoxicities of compound 5 and cisplatin in ovarian and melanoma cancer cell lines was 
reported previously. In this work, we expanded the study to include several other cancer 
cell lines and to show low micromolar potency (4 μM) in a prostate cancer cell line, 
DU145. Despite previous success, a common problem associated with platinum 
compounds is their side effects originating from a lack of tumor selectivity. Selective 
targeting can be achieved by utilizing characteristic features of the cancer cells, such as 
enhanced glucose uptake. Therefore, it was of interest to examine compound 5 uptake 
and compare cytotoxicities (IC50 values) for DU145 prostate cancer and the 
corresponding normal cells. Compound 5 showed an 18-fold higher potency towards 
DU145 compared to normal cells, suggesting selectivity towards the cancer cells. A 
quantitative analysis of Pt levels in the cells was carried out using inductively coupled 
plasma mass spectrometry (ICP-MS), to determine whether the biological differences 
were due to higher accumulation of compound 5 in the cells or some other factor. There 
is a 24-fold higher accumulation of 5 in cancer cells over normal cells, whereas for 
cisplatin it is 18-fold. Therefore, these findings suggest the potential of using 






The drawbacks associated with the antitumor drugs have stimulated the search for 
new compounds with improved pharmacological properties. In the search for new 
compounds, one of the first steps is testing their antitumor activity against a panel of 
cancer cells.
7,201,211
 This approach will facilitate identification of tumor cells that are 
targeted as well as determine the level of selectivity of the chosen compounds. The cell 
studies together with biochemical assays will give insight into the mechanism and 
facilitate the development of compounds with an improved spectrum of activity. 
Although most of the existing anticancer drugs are believed to have a similar mechanism 
of action for cancer cell apoptosis by binding to DNA, their potency towards different 
cancer types varies.
7
 This difference could be due to the inherent properties of the cancer 




5.2.1 The MTT assay 
There are several ways to quantify viable cells following drug treatment. 
Traditional methods include counting cells using a hemocytometer and colony 
counting.
212
 However, these methods can be tedious and time consuming. Another widely 
used method is the radionuclide incorporation assay, which can be expensive and time-
consuming.
212
 Compared to these methods, the MTT assay is a quantitative, sensitive, 
and reliable assay for cell viability measurements.
129,213
 It is a colorimetric assay to 
indicate the cellular metabolic activity. MTT is a yellow-colored, water-soluble dye that 
can readily undergo reduction, primarily by mitochondrial dehydrogenases, to produce 
purple colored formazan crystals.
213




cells, in which MTT is taken up through endocytosis, and the formazan product is 
transported and crystallized on the cell surface.
214
 The intensity of the color is therefore 
correlated with the number of live cells present. The absorbance is read (usually between 
500 and 600 nm) after dissolving the formazan crystals in DMSO.
130
 The absorbance is 
compared to the controls and normalized to calculate the percent survival of cells. The 
cytotoxicity of the drugs is given as the IC50 value after exposing the cells to different 
concentrations of the drug. The IC50 value is the drug concentration at which half of the 
cell activity is inhibited.
215
 This value is obtained from a graph plotted against the percent 
survival and the relevant drug concentrations. Although used for cell viability, this assay 
can also be used to analyze cell proliferation.
213
 The MTT assay has been widely adopted 
due to its simplicity and sensitivity. However, certain parameters have to be taken into 
consideration when optimizing the assay to obtain the best signal intensity. These include 
the number of cells and their metabolic activity, the concentration of MTT, and the length 
of incubation.
213
 There are other tetrazolium reduction assays that are similar to MTT.
130
 
The most commonly used tetrazolium compounds include MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), XTT (2,3-bis-(2-








5.2.2 Potency of major platinum-based drugs in human cancer cell lines 
Cisplatin, oxaliplatin, and carboplatin are FDA-approved, platinum-based 
anticancer drugs that are used around the globe.
17






 Their potency has been widely documented with different cancer 
cell lines using the above-mentioned methods.
216,217
 The IC50 value for a drug in the same 
cell line can vary depending on many parameters, including the assay type and treatment 
period.
215
 Table 5.1 summarizes the IC50 values that have been reported for the major 
platinum-based anticancer drugs in several human cancer cell lines. 





cisplatin oxaliplatin carboplatin 
MDA-MB-231 1.4 ± 0.2 (120 h*)
216
 23 ± 0.1 (72 h*)
217
 8.3 ± 0.3 (120 h*)
216
 
MDA-MB-435 5.8 ± 4 (24 h*)
191
 12.7 ± 5.6 (24 h*)
191
 - 
H1299 21.4 ± 4 (72 h*)
218
 - 19.3 ± 3 (5 days*)
219
 
DU145 3 (72 h*)
220
 - 10 ± 0.7 (5 days*)
219
 
LNCaP 15.9 ± 4.7 (72 h)
221
 >50 (24 h*)
222
 >100 (72 h)
221
 
IGROV1 5.6 ± 1.3 (24 h*)
191
 8.08 ± 2.9 (24 h*)
191
 49 ± 15 (96 h)
223
 
A549 2.7 ± 0.5 (120 h*)
216
 0.86 ± 0.09 (72 h*)
165
 20 ± 0.9 (120 h*)
216
 
HOP-92 3.6 ± 3.2 (24 h*)
191
 2.70 ± 0.6 (24 h*)
191
 - 
COLO205 16.7 ±7.2 (24 h*)
191
 2.8 ± 0.64 (24 h*)
191
 69 (72 h) 
MCF7 15.6 ± 6.4 (24 h*)
191
 1.7 ± 0.54 (24 h*)
191
 62.2 (72 h) 
HeLa 30. 4 ± 11 (24 h*)
224
 11.8 ± 1.4 (72 h*)
225
 5.4 ± 1.5 (96 h*)
151
 
The drug treatment times are given in parenthesis. The IC50 values were determined by 
*the MTT or MTS assay,  , or  cell survival assay. 
MDA-MB, IGROV1: ovarian cancer; H1299: lung cancer; DU145, LNCaP: prostate 
cancer; A549: lung cancer; HOP: non small cell lung cancer; COLO205: colorectal 
cancer; MCF7: breast cancer; HeLa: cervical cancer 
 
5.2.3 Potency of carbohydrate-derived platinum(II) analogs  
 Several challenges such as low water solubility and high toxicity for normal cells 






Carbohydrates are a class of bioavailable ligands that are non-toxic, inexpensive, and 
easy to modulate in order to introduce desirable properties for drug applications.
151
 
Multiple attempts have been made to synthesize platinum(II) and (IV) complexes with 
carbohydrates ligands, as described in the previous chapters of this thesis.
121,151,158,211
 In 
this chapter, only the activities of platinum(II)-carbohydrate complexes will be discussed. 
Carbohydrate conjugation has been shown to help overcome some of the above-
mentioned drawbacks associated with traditional drugs. For example, a series of 
glycoconjugated oxaliplatin derivatives were shown to have 50- to 120-fold increases in 
water solubility at 25 C compared to the parent compound oxaliplatin.
211
 Another 
feature that has been explored with glycoconjugated Pt(II) complexes is their selectivity 
towards tumors.
81,165,211
 According to the Warburg effect, tumor cells have a higher 
metabolism, which is necessary to promote tumor growth, proliferation, and 
survival.
226,227
 An outcome of this increased metabolism is increased glucose uptake and 
higher glucose transporter (GLUT) expression on the cell membrane to facilitate the 
uptake.
156,165
 Therefore, this is a feature of malignant cells that can be exploited when 
designing glycoconjugated platinum complexes for selective targeting. There are 12 
members of the glucose transporter gene family, in which GLUT1 is ubiquitously 
expressed in all tissue types.
154
 Other than for achieving selectivity, glycoconjugation can 
also be used as a strategy to overcome cross-resistance due to decreased drug uptake.
165
 
Tables 5.2 and 5.3 show potencies of a few glycoconjugated platinum(II) analogs 
with promising activity in comparison to clinically available platinum(II) drugs. Figure 
5.1a shows glucose, mannose, and galactose-conjugated oxaliplatin derivatives, in which 




water solubility and comparable cytotoxicity to oxaliplatin (Table 5.2) in the tested 
human cancer cell lines.
165,211
 Additionally, GLUT1-dependent uptake of these 
derivatives was observed in HT29 cells that overexpress glucose transporters.
165,211
 The 
structure of a simple diaminosugar-platinum(II) complex with a 2,3-diamino-2,3-
dideoxy-D-glucose non-leaving group ligand and different leaving group ligands are 
shown in Figure 5.1b.
158
 The cytotoxicity for these derivatives was determined in human 
cancer cell lines using the MTT assay and shown to have low micromolar range IC50 
values (≤10 μM) as given in Table 5.3. 
 
Figure 5.1. The chemical structures of sugar-conjugated platinum(II) complexes. 
(a) Sugar-conjugated (trans-R,R-cyclohexane-1,2-diammine)-2-flouromalonato 
platinum(II) and (b) a diaminosugar-platinum(II) complex with different leaving group 
ligands are shown. 
 
Table 5.2. Cytotoxicity of sugar-conjugated oxaliplatin derivatives (Figure 5.1a) in 






DU145 MCF7 HT29 H460 
A 5.9 ± 0.16 0.61 ± 0.13 0.53 ± 0.16 11 ± 0.11 
B 2.6 ± 0.18 0.41 ± 0.09 2.2 ± 0.18 10 ± 0.15 
C 5.1 ± 0.14 0.41 ± 0.09 1.1 ± 0.12 10 ± 0.15 
oxaliplatin 2.1 ± 0.16 0.79 ± 0.11 5.1 ± 0.20 22 ± 0.17 
The IC50 values were determined by the MTS assay for 72 h. DU145: prostate cancer; 







Table 5.3. Cytotoxicity of diaminosugar-platinum(II) complexes (Figure 5.1b) in 







D 5.1 ± 0.3 7.3 ± 0.8 
E 4.1 ± 0.1 10 ± 1 
F 6.3 ± 0.4 23 ± 7 
carboplatin 0.52 ± 0.01 5.4 ± 1.5 
oxaliplatin 0.34 ± 0.09 0.3 ± 0.08 
 The IC50 values were determined by the MTT assay 




Platinum-based drugs are widely used in cancer therapy. Successful drug 
candidates are expected to show improved cytotoxicity, reduced side effects, and/or 
different mechanisms of action compared to the currently available drugs.
7
 One purpose 
of this study was to evaluate the cytotoxicity of 5 in human cancer cell lines using the 
MTT assay (in collaboration with Dr. Fidelis Ndombera and Bett Kimutai). The percent 
survival of the cell lines was measured in response to compound 5 compared to the parent 
platinum drug, cisplatin. High cytotoxicity in tumor cell cultures doesn’t necessarily 
mean a compound is only cytotoxic towards the cancer cells; it could be toxic for normal 
cells as well. Therefore, one of the goals of this thesis was to discriminate between toxic 
and antitumor effects of 5 by parallel testing on normal cells. I hypothesized that the 
sugar group in 5 would facilitate selective uptake of the complex in cancer cells due to 
the higher GLUT1 transporter expression compared to normal cells. Therefore, the 
second objective of this study was to determine the level of selectivity of the compound 




compared by using the MTT assay. Thirdly, the platinum levels were quantified in cancer 
and normal prostate cells to compare the cellular uptake levels of 5.  
5.4 Results and discussion 
5.4.1 Cytotoxicity of 5 in human cancer cell lines 
 The in vitro antitumor activity of compound 5 was previously reported for two 








median effect dose (μM) 
compound 5 cisplatin 
A2780S 2.5 3.3 
MeWo 11.2 8 
             A2780S: ovarian cancer; MeWo: human melanoma  
             Cytotoxicity was measured by clonogenic survival  




Previously, compound 5 showed comparable cytotoxicity as cisplatin with 
A2780S and MeWo cell lines.
82
 The reported low micromolar potency of 5 encouraged 
me to evaluate its cytotoxicity in several other cancer cell lines with different origins in 
order to relate the molecular structure of 5 with cytotoxicity, as compared to cisplatin. 
The IC50 values were determined by the dose dependence of cell viability after exposure 
to 5 and cisplatin (Figures 5.2 and 5.3) for 48 to 72 h (Chapter 2, Section 2.4.18). The 
treatment time was increased from 48 h to 72 h in the prostate cell lines to compare the 
values with literature. The data are given in Table 5.5. The IC50 values are the averages 
of at least two trials (except for 5 with MDA-MB-453 and LNCaP cell lines, in which 








Figure 5.2. Dose-response curves for cisplatin and compound 5 by using the MTT 
assay for human cancer cell lines. The drug concentration that gives the 50% cell 
viability (IC50 values) and the errors were obtained by a nonlinear regression curve fitting 
by using the GraphPad software.  
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Figure 5.3. Dose-response curves for cisplatin and compound 5 by using the MTT 
assay for human cancer cell lines. The drug concentrations that give the 50% cell 
viability (IC50 values) and the errors were obtained by a nonlinear regression curve fitting 




















































































































Table 5.5. The IC50 values for compound 5 and cisplatin in human cancer cell lines 
as evaluated by the MTT assay 
 




compound 5 cisplatin 
HeLa cervical 48 h 184 ± 41 23 ± 1.4 
LNCaP prostate 64 h 63 4 ± 0.6 
DU145 prostate 72 h 4 ± 0.7 2 ± 0.7 
H1299 non small cell lung 48 h 131 ± 8 33 ± 3 
MDA-MB-231 breast 48 h 106 ± 30 17 ± 4 
MDA-MB-453 breast 64 h 53 10 ± 0.7 
 
Notably, in the prostate cancer cell line DU145, compound 5 has comparable 
cytotoxicity to cisplatin with an IC50 value of 4 ± 0.7 μM. It is interesting to see a higher 
potency of 5 in DU145 cells irrespective of the previously observed slower reaction 
kinetics. This result suggests that DU145 cells are more sensitive to 5 compared to other 
tested cell lines. Multiple cancers have shown characteristic overexpression of genes that 
are related to glycolysis.
156
 Prostate cancer is one of them, and the cells are particularly 
prone to overexpression of GLUT1, which is responsible for sugar uptake.
156
 The DU145 
cell line has been previously used for cell uptake studies with glycoconjugated 
platinum(II) complexes due to this reason.
83,165
 Thus, higher sensitivity of DU145 
towards glycoconjugated 5 compared to other cancer cells may be partly due to the higher 
accumulation of the compound in the cells, which will be discussed later.  
The IC50 values of 5, however, are higher than that of cisplatin in all the other cell 
lines tested (Table 5.5). Cervical, breast, and lung cancer cell lines do not overexpress 
the GLUT1 gene,
156
 which is also reflective in the cell toxicity assay data with higher 




The activity of cancer drugs depends on many factors, including cell entry, drug 
activation, binding to targets, and inhibition of function.
211
 These factors vary depending 
on the characteristics of the tumor, drug-resistance mechanisms, and features of the drug 
itself, and therefore, mediate the potency of the drug in a certain cell line. Additionally, 
the assay type and the treatment times also affect the IC50 values. Considering the slower 
kinetics of 5, increased treatment times would result in better cytotoxicity. In a previous 
study, a similar trend was seen for carboplatin in which a higher cytotoxicity was 
observed after a 24 h exposure period compared to a 1 h exposure period in six human 
ovarian cell lines.
212
 Overall, compound 5 could be considered as a lead compound for 
treating cancers with higher GLUT expression. Future studies can be carried out to test 
the potency of compound 5 on other cancer cells lines that overexpress GLUT. 
5.4.2 Cytotoxicity of 5 in normal human prostate cell line 
 MTT assays were carried out to investigate the selectivity of compound 5 towards 
the cancer cells over normal cells. Since 5 exhibited more cytotoxicity towards DU145 
prostate cancer cells, the corresponding normal prostate epithelial cell line, RPWE1, was 
used to test for selectivity. Furthermore, DU145 cells have been shown to overexpress 
GLUT, which is not the case for RPWE1. The hypothesis is that 5 would show higher 
cytotoxicity against DU145 than RWPE1 due to GLUT-dependent uptake of the 
compound. In fact, the IC50 values obtained from the MTT assays for 5 show an 18-fold 
higher cytotoxicity towards DU145, whereas cisplatin did not show such a difference 
(Table 5.6). The higher toxicity and selectivity of 5 towards the DU145 cancer cell line 
compared to the normal cell line could be due to its higher accumulation in the cell, 




Table 5.6. In vitro cytotoxicity of 5 and cisplatin on prostate cell lines as evaluated 
by the MTT assay 
 
cell line cell type treatment 
time 
IC50 (μM) 
compound 5 cisplatin 
DU145 prostate cancer 72 h 4 ± 0.7 2 ± 0.7 
RWPE1 normal prostate 72 h 72 ± 2.6 4 ± 0.1 
 
5.4.3 Quantification of 5 in cells using ICP-MS 
In order to evaluate whether the cytotoxicity difference observed in Section 5.4.2 
is due to Pt accumulation differences in the cells, whole cell Pt levels were quantified 
after treatment. This was done by ICP-MS. First, the experimental protocol for sample 
preparation and ICP-MS analysis method were optimized to obtain reproducible data to 
evaluate the platinum content in the whole cell.
229
 The experiment was started with the 
same cell number (4.6×10
5
) in each plate (Chapter 2, Section 2.4.19). To minimize the 
effects from the media, both cell lines were incubated in the same keratinocyte media 
during the drug treatment. Cells were treated with 50 μM Pt(II) compounds for 2 h and 
the cells were washed several times with PBS to remove excess Pt. Cells were 
trypsinized, pelleted, and digested with nitric acid (16 h), and then the total cellular 
platinum content was determined by ICP-MS. As shown in Figure 5.4, compound 5 
displays a level of 31.5 nmol Pt per 10
6
 cells in cancer cells, which is 24-fold higher 
compared to the level in normal cells. Compared to cisplatin, 5 shows a 1.3-fold selective 
accumulation in cancer cells over normal cells after 2 h treatment. Although cisplatin 
accumulation levels in cancer over normal cells show an 18-fold difference, the 
cytotoxicity is similar in the two cell lines. This may be due to the increased activity of 





Figure 5.4. Accumulation of Pt(II) compounds in prostate cancer (DU145) and 
normal (RPWE1) cells. The cells were treated with 50 μM compound for 2 h and the Pt 
levels were quantified by ICP-MS. The errors were calculated from two independent 
trials. 
 
The strategy of glycoconjugation for targeted delivery via glucose transporters has 
been explored previously with oxaliplatin derivatives;
83,121,165,211
 however, this effect has 
not been examined with cisplatin derivatives such as 5. A recent study from the Lippard 
group focused on glucose-platinum(II) conjugates for cancer cell targeting.
83
 In that 
study, glucose-oxaliplatin derivative uptake levels were compared between DU145 and 
RWPE2 and showed a 4-fold preference for cancer cells, which was discussed by the 
authors as a significant difference.
83
 Moreover, the same compound showed a 2-fold 
reduced cancer cell viability compared to the normal cells. In comparison, we were able 
to show that compound 5 has better selectivity towards DU145 cells with a significant 
difference in the Pt uptake (23-fold) and cytotoxicity (18-fold) compared to RPWE1. 
While the overall results from this study showed the potential of compound 5 in DU145 
cell line, it is worth exploring ways to improve the activity and selectivity towards other 
cancer types as well. Glycoconjugated compounds can be synthesized with modifications 
to the sugar, varying linker sizes, and with different leaving group ligands to optimize the 




glycoconjugated anticancer agents for selective targeting, but also sheds light on the 

























Electrostatics play an important role in RNA-drug interactions; however, studying 
these interactions experimentally in solution can be challenging. Positively charged drug 
molecules such as aminoglycosides are attracted to the negatively charged RNA. Other 
ions present in the environment affect the electrostatic properties and influence these 
interactions. Based on a previous study from our lab that showed salt-dependent cisplatin 
coordination rates to RNA, we postulated that positively charged aminoglycosides could 
change the platination rates by competing with mono-activated cisplatin for the target 
(H69 RNA). Herein, we describe a kinetic method to monitor aminoglycoside 
interactions with RNA using cisplatin coordination rates. The platination rate was found 
to decrease significantly in the presence of aminoglycosides. This change in mono-
activated cisplatin reaction rates indicated the involvement of electrostatics in 
aminoglycoside-RNA interactions. In addition, we postulated that the pseudouridine (Ψ) 
modifications present in a rRNA construct used in this report were perhaps important for 
the binding of the aminoglycosides. However, a significant difference between modified 
and unmodified H69 RNA constructs was not observed when probed with the platination 
kinetics. Overall, these findings are important for providing information on drug-RNA 
interaction mechanisms, improving cationic drugs for nucleic acids, identifying unique 







The phosphate backbone of nucleic acids makes them highly charged, anionic 
biopolymers.
230
 Therefore, electrostatics play an important role in various ligand-nucleic 
acid interactions. Specifically, electrostatic microenvironments created by RNA folding 
are important for their biological function, stability, and ligand interactions.
192
 For 
example, local electrostatic pockets created by the ribosome are important for its key 
interactions with mRNA and tRNA.
231
 Furthermore, RNA-protein interactions are 
governed by electrostatic interactions,
232
 which has been established in numerous 
examples, including transcription activating (Tat) protein binding to trans-active 
responsive element (TAR) RNA and Rev-peptide binding to Rev-response element 
(RRE) RNA.
232,233
 Additionally, some drugs that target the ribosome rely on the 
electrostatic interactions to bind to their target sites.
120
 For example, the aminoglycoside 
antibiotics, including compounds neomycin, kanamycin, and paromomycin (Figure 6.1), 
bind to the ribosome and interfere with various steps in protein synthesis in bacteria.
120
 
Neomycin and paromomycin, which are the focus of this chapter, interact with the h44 
region of the 16S rRNA to induce codon misreading and decrease translation 
fidelity.
108,109
 Crystal structures have also revealed a secondary binding site for neomycin 
and paromomycin at H69 of 23S rRNA.
106,110,111
 Interactions in the H69 major groove are 
believed to inhibit the recycling and translocation steps of protein synthesis.
112
 The 
positively charged amine groups of aminoglycosides form electrostatic interactions with 
RNA.
122,123
 In addition, anticancer drugs such as cisplatin are also shown to bind to 
RNA.
234




species. Electrostatic interactions between the positively charged cisplatin and the 
negatively charged RNA attract the two species for the coordination reaction to occur.  
Figure 6.1. Chemical structures of aminoglycosides at pH 7. The structures of 
neomycin, paromomycin, and streptomycin at pH 7 with the pKa values of amino and 
guanidinium groups are shown. 
 
As mentioned before, RNA microenvironments and their interactions with other 
ligands are important for RNA biology. Inside living cells, biological molecules, 
including RNA are in constant contact with cations.
230,235




neutralize the negative charge of RNA and facilitate folding and stabilizing.
235,236
 They 
also play an important role in ligand interactions.
230,235
 Numerous studies have shown 
salt-dependent binding and rate constants for RNA-ligand interactions.
122,237-243
 
Additionally, a broad kinetic study done by Dr. Dedduwa-Mudalige determined the salt-
dependent coordination rates and electrostatics in cationic metal complexes-rRNA 
reactions using mono-activated cisplatin.
50
 The salt-dependent nature of mono-activated 
cisplatin coordination to RNA suggested the possibility of using the cisplatin kinetics as a 




bound aminoglycosides with the Rev-responsive element (RRE) of HIV-1 mRNA were 
shown to readily dissociate from the mRNA at relatively high salt concentrations.
244
 We 
hypothesized that, under pseudo-first-order conditions, positively charged cisplatin would 
compete and cause dissociation of aminoglycosides in a similar fashion, and then 
coordinate to RNA to block further interactions. Depending on the charge state and 
binding mode of the drug, the degree of competition could vary, potentially being 
reflected through the cisplatin coordination rate. This knowledge was employed in 
developing a tool to monitor positively charged aminoglycoside binding to H69. 
Computational studies can predict the varying electrostatic potentials on RNA and 
potential locations of ligand interactions.
192,245,246
 However, there is a lack of methods to 
evaluate the role of electrostatics in RNA-ligand interactions experimentally. This 
chapter describes a method to monitor the RNA-aminoglycoside interactions by using 
platination kinetics, and therefore elucidate the electrostatic involvement in drug binding 
to RNA.  
6.3 Objectives 
 The ribosome is an important drug target due to its abundance, accessibility, lack 
of repair mechanisms, and vital biological function in the cell.
97
 One of the common 
features of the drugs that target RNA is their positive charge, which facilitates the initial 
binding step through electrostatic contacts. A lack of experimental methods to support the 
role of electrostatic interactions between RNA and drugs delays the drug development 
process against resistant pathogens. The primary objective of this work was to use of 
cisplatin kinetics to probe and determine the electrostatic dependence of polycationic 




Two model H69 rRNA hairpins (Figure 6.2) were chosen for this study. The H69 
RNA hairpin possesses three pseudouridine nucleotides (Figure 6.2) that have been 
shown to be involved in regulating the H69 structure, stability, and function.
247-250
 The 
contribution of pseudouridines to the electrostatics of nucleic acids have been reported 
previously.
251
 Therefore, two H69 constructs containing either uridines (unmodified H69) 
or pseudouridines (modified H69) were studied in order to understand the influence of 
the modifications on electrostatics and aminoglycoside binding of rRNA. 
 
Figure 6.2. Structures of RNA constructs used in the kinetic study. Modified () 
and unmodified (UUU) H69 rRNA constructs are shown, in which  is pseudouridine 
(shown to the right).   
 
6.4 Results and discussion 
 
The mono-activated cisplatin coordination rates to H69 were obtained in the 
presence of 1, 3, and 6 µM neomycin, paromomycin, and streptomycin as described in 
Chapter 2, Section 2.4.10. A representative result for the kinetic experiment in the 
presence of 1 µM neomycin is shown in Figure 6.3a. The fraction of unreacted RNA was 
plotted over times to obtain the platination rates in the presence of aminoglycoside 
(Figure 6.3c). The control platination reaction contained no aminoglycosides (Figure 




used as a negative control.
112
 The disappearance of RNA was quantified rather than 
appearance of products since multiple products are observed. 
Figure 6.3. Reaction kinetics of mono-activated cisplatin and RNA constructs in the 
presence and absence of aminoglycoside. Autoradiograms for unmodified and modified 
H69 (a) in the presence of 1 μM neomycin and (b) absence of aminoglycoside are shown 
([RNA] = 0.7 μM, [mono-activated cisplatin] = 188 μM; 10 mM K2HPO4/KH2PO4, pH 
6.2, with 20 mM NaClO4, 37 °C). Single-exponential-decay fits for the disappearance of 
unreacted RNA (c) in the presence of 1 μM neomycin and (d) absence of aminoglycoside 
as a function of time (min) are shown. 
 
The kobs and k2,app values for both modified and unmodified H69 in the presence of 




the presence of neomycin (>2-fold) and paromomycin (>1.3-fold) compared to the no 
aminoglycoside control, revealing that cisplatin-RNA interactions are competing with the 
aminoglycosides.  
Table 6.1. Observed pseudo-first-order rate constants, kobs, and the second-order 
rate constants, k2,app for the reactions of mono-activated cisplatin with H69 RNA in 
















no aminoglycoside 0 14.8 ± 2.9 7.9 ± 1.6 
neomycin 
1 6.0 ± 1.1 3.2 ± 0.6 
3 2.3 ± 0.4 1.2 ± 0.2 
6 0.7 ± 0.1 0.4 ± 0.05 
paromomycin 
1 10.8  ± 2.7 5.8 ± 1.4 
3 4.2 ± 1.0 2.2 ± 0.5 
6 3.0 ± 0.9 1.6 ± 0.5 
streptomycin 
1 17.0  ± 3.7 9.0 ± 1.9 
3 15.3 ± 2.4 8.1 ± 1.3 
6 18.0 ± 1.9 9.6 ± 1.1 
modified H69 
no aminoglycoside 0 14.1 ± 3.1 7.5 ± 1.7 
neomycin 
1 3.9 ± 0.9 2.1 ± 0.5 
3 1.8 ± 0.3 0.9 ± 0.2 
6 1.0 ± 0.2 0.5 ± 0.1 
paromomycin 
1 8.8 ± 1.7 4.7 ± 0.9 
3 1.5 ± 0.7 1.1 ± 0.4 
6 1.6 ± 0.5 0.9 ± 0.3 
streptomycin 
1 13.6 ± 2.1 7.2 ± 1.1 
3 12.1 ± 2.1 6.4 ± 1.1 
6 18.2 ± 2.4 9.7 ± 1.3 
[RNA] = 0.7 μM, [cisplatin] = 188 μM; 10 mM K2HPO4/KH2PO4, pH 6.2, with 20 mM 






Figure 6.4. A comparison of platination rates in the presence and absence of 
aminoglycosides. The platination rates obtained with unmodified H69 (UUU) and 
modified H69 (ΨΨΨ) are shown. Reaction conditions: [RNA] = 0.7 μM, [mono-activated 
cisplatin] = 188 μM, [aminoglycoside] = 1, 3, or 6; 10 mM K2HPO4/KH2PO4, pH 6.2, 
with 20 mM NaClO4, 37 °C. 
 
The platination rate differences in the presence of varying aminoglycosides for 
unmodified H69 construct are summarized in Figure 6.4. Both RNA constructs show a 
decrease in cisplatin reactivity as the aminoglycoside concentration increases. Analogous 
to the impact of salts on cisplatin-RNA interactions as reported previously,
50
 a similar 
influence can be expected for coordination of mono-activated cisplatin in the presence of 
positively charged aminoglycosides. Association of positively charged aminoglycosides 
with H69 screens the negative charges on RNA. Therefore, neutralizing effects by 
positively charged ligands decrease the cisplatin reactivity on RNA.
50
 Specifically, 
between 1 and 6 μM neomycin concentrations, there is an 8-fold decrease in the 
platination rate compared to a 3.6-fold decrease for paromomycin with unmodified H69. 
Comparison between neomycin and paromomycin at every concentration level shows 
higher cisplatin reactivity for paromomycin (about a 2-fold difference) compared to the 
no aminoglycoside control. The changes in the platination rates in the presence of 
aminoglycosides could be explained by differing electrostatic interactions. Neomycin has 




conditions (pH=6.2) (Figure 6.1).
252
 Paromomycin has four out of five amino groups that 
are positively charged at pH 6.2. The observed cisplatin kinetics differences for neomycin 
and paromomycin can be rationalized by the different charges of the aminoglycosides, in 
which neomycin has one extra positive charge that can screen the RNA more effectively 
than paromomycin, thus decreasing the reactivity of cisplatin. The differences in 
platination rates correlate well with aminoglycoside binding preferences to H69. For 
instance, neomycin has tighter binding to unmodified H69 than paromomycin (Kd values 
of 0.3 and 5.4 μM, respectively). Cisplatin binding rates are proportional to the Kd values 
of tested aminoglycosides.  
The streptomycin control has the highest platination rates. Streptomycin has two 
guanidinium groups with pKa values of 12.5, which are positively charged at the given 
conditions, but this molecule has been reported previously to not bind to the H69 
region.
112
 Thus, in the presence of streptomycin, the cisplatin-binding rate does not 
change significantly from the rate in the absence of aminoglycoside. These results 
indicate that electrostatic contacts are likely to be important for aminoglycoside binding 
to RNA. Therefore, as the overall positive charge of the aminoglycoside is decreased, the 
competitive effect of mono-activated cisplatin increases.  
Aminoglycoside dependent platination rates were determined in a buffer 
containing 32 mM (12 mM K
+
 + 20 mM Na
+
) total monovalent cations. In the previous 
salt-dependent studies,
50
 as the total cation concentration increased from 32 to 112 mM, 
the platination rate (k2) decreased 6-fold for unmodified H69.
102
 This is analogous to the 
decrease in the platination rate with increasing aminoglycoside concentration from 0 to 6 




dependent kinetic data) and 15-fold (neomycin-dependent kinetic data) decrease is 
observed. This result indicated that in the presence of aminoglycosides (as low as 6 μM), 
the decrease in platination rate is more prominent than in the presence of higher salt 
concentration (112 mM). Since the kinetic model for platination kinetics involves a 
preassociation step and a coordination step,
235
 aminoglycosides would likely interfere 
with not only the preassociation step but also the direct coordination step due to 
overlapping binding locations. In fact, previous studies have shown cisplatin and 
aminoglycosides binding at the H69 stem.
95,111
 Specifically, RNase T1 probing, MALDI 
MS, and dimethylsulfate (DMS) mapping revealed platination at G1921-G1922 and 
G1906-G1907.
95
 Neomycin and paromomycin binding interactions at the H69 stem has 
been shown by Dr. Sakakibara by using DMS footprinting.
253
 These results were also 
consistent with bacterial 70S ribosome X-ray crystal structures with neomycin bound to 
the H69 stem region near residues G1906, G1921, and G1922.
111
 Therefore, the observed 
prominent aminoglycoside-dependent rate changes could be the result of increased 
competition that cisplatin faces when coordinating to RNA. Overall, the results 
demonstrated that platination rate variations can be used as an indication of 
aminoglycoside or other cationic compound interactions with RNA.  
In aminoglycoside-dependent studies, platination rate differences between 
modified and unmodified H69 were not observed, implying that pseudouridine 
modification does not impact aminoglycoside interactions with H69. This result also 
correlates with the similar Kd values for the two RNA constructs as determined by ESI 
MS.
254
 This could be due to minimal influence of Ψ modifications on the global 








In conclusion, this study showed the utility of coordinating compounds, such as 
cisplatin, as probes to obtain information about cationic, non-metallic ligand interactions 
with RNA. As hypothesized, the effects of the bound aminoglycosides were to slow 
down the cisplatin coordination rates, thereby reflecting different affinities of 
aminoglycosides to H69. This method was sensitive enough to detect differences in RNA 
binding by neomycin and paromomycin, which differ by a single charge. Moreover, 
cisplatin kinetics could be used to evaluate the effects of varying pH on cationic drug-
RNA interactions. This tool could also be expanded to probe aminoglycoside binding to 
other RNA or DNA targets. Overall, this study highlighted the importance of electrostatic 
interactions in drug binding, and therefore provides insight into drug binding modes that 
















OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 Overall conclusions 
With the discovery of cisplatin anticancer activity, a large number of platinum-
based compounds have been developed and tested for their activity. Only a few of those 
have entered the clinic. Even 40 years after the discovery of cisplatin, there are still wide 
gaps in our understanding of its mechanism of action.
3
 Also, the clinical success of these 
drugs has been limited due to the intrinsic and acquired resistance and side effects.
255
 
However, a deeper understanding of how these drugs work has opened the door to 
explore new platinum-based anticancer drugs.
7,90
 Many researchers are investigating the 
biochemical and biomolecular aspects of platinum-based drug mechanism in the hope of 




A characteristic feature of platinum-based complexes is the ability to replace the 
leaving- and/or non-leaving group ligands with a variety of functional groups. These 
ligands determine different aspects of the compound activity.
73
 Careful selection of the 
ligands facilitates tuning of cytotoxic characteristics of the complexes. Since one of the 
drawbacks associated with the current platinum anticancer drugs is off-target reactions 
and resistance through increased cytosolic deactivation, researchers have aimed at 
decreasing reactivity through the introduction of bulky non-leaving group ligands.
255
 
Decreased reactivity was also expected to reduce the toxicity, as was the case with 
carboplatin.
74
 Another approach is to introduce ligands with other biological roles in the 
cell to reduce the toxicity and improve selectivity.
255




of this thesis focused on studying a carbohydrate-linked cisplatin analog, cis-
dichlorido[(2-β-D-glucopyranosidyl)propane-1,3-diammine] platinum(II) (compound 5), 
which has a bulky, biologically active non-leaving group ligand. Although there were 
multiple cellular studies with such complexes, biochemical studies to understand the 
reactivity, structural effects, and impact of the non-leaving group ligand were lacking. 
Therefore, studies in this thesis work were carried out to investigate the reaction kinetics 
and selectivity of compound 5 with nucleosides and oligonucleotides in order to 
understand the impact of the carbohydrate non-leaving group ligand on its reactivity. 
One of the main goals of this thesis was to identify the kinetics of carbohydrate-
linked platinum(II) compound, 5, in the context of nucleic acids and their building blocks 
(e.g., nucleosides). Impact of the carbohydrate moiety of compound 5 on the reaction 
kinetics and nucleic acid binding preference were discussed in Chapter 3 and 4, in the 
context of steric and electrostatic properties. A comparison was made with the parent 
compound, cisplatin, which is sterically less crowded.  Mono-activated compound 5 
showed ≥2.5-fold slower reaction kinetics compared to mono-activated cisplatin with 
nucleosides, a DNA oligonucleotide (13.7-fold slower), and an RNA oligonucleotide 
(3.6-fold slower). The slower kinetic effect can be attributed to the bulkier carbohydrate 
moiety of the complex, in which the reactivity may be reduced due to the crowding at the 
Pt reactive center. This observation suggests that compound 5 might have reduced off-
target binding.  
Furthermore, mono-activated 5 showed preference towards RNA over DNA (1.7-
fold) in contrast to cisplatin, which preferred DNA. Ribosome-targeting drugs such as 




RNA-binding preference and multiple hydrogen-bond donating and accepting sites, 
compound 5 may have target sites within the ribosome. Therefore, ribosome-probing 
studies were carried out to locate the ribosome binding sites of the compound. Compound 
5 showed binding at functionally important regions of ribosomal RNA such as the A site, 
the 790 loop, and H69. The binding sites overlapped with cisplatin and other common 
drug binding sites, suggesting that the binding could potentially disrupt the protein 
translation process. Therefore, further efforts towards the design of carbohydrate-linked 
platinum analogs for the treatment of cancers might include the RNA as a potential 
target. The structural effects caused by compound 5 binding were also analyzed using 
plasmid and short oligomer DNA as described in Chapter 4. Compound 5 showed 
unwinding and bending of DNA, similar to cisplatin, even though the kinetics appeared 
to be slower than cisplatin. To best of our knowledge, this is the first attempt to determine 
reaction kinetics and structural effects at the oligonucleotide level for a carbohydrate-
linked Pt(II) compound. Our studies were carried out to understand the influence of the 
sugar moiety on the reactivity.  
A large number of new Pt-based compounds have been synthesized and tested 
over the past few decades.
7,150,162
 Unfortunately, very few have entered clinical trials, and 
some very promising drug candidates were abandoned due to their toxic effects.
255
 One of 
the reasons for this is that testing in model cell lines poorly reflects the clinical situation. 
For example, high cytotoxicity in tumor cells doesn’t necessarily mean it is only 
cytotoxic towards the cancer cells; the compound could be toxic to normal cells as well. 
Therefore, one of the goals of this thesis work was to discriminate between toxic and 




DU145 prostate cancer cells against normal prostate cells provided evidence for the 
targeted effect of glycoconjugation as described in Chapter 5. This effect could be due to 
the utilization of highly expressed glucose transporters (GLUT) on DU145 cells for 
compound 5 uptake as opposed to normal cells, in which the GLUT expression is low.
165
 
Platinum levels upon compound treatment were quantified by using ICP-MS to further 
suggest the selective accumulation of 5 on cancer cells vs. normal cells. Compound 5 
showed higher accumulation (24-fold) in DU145 cancer cells compared to normal cells, 
which makes 5 a promising candidate for targeted delivery compared to cisplatin.  
Modifying existing drugs to use them as tools to obtain information about drug-
target interactions is another approach. Chapter 6 describes an attempt to establish 
cisplatin as a tool to predict the RNA-cationic drug interactions. Both cisplatin and 
aminoglycosides use electrostatic interactions to bind to their target. Therefore, cisplatin 
binding rates were sensitive to the cationic aminoglycoside binding to RNA, identifying 
drugs that interact with RNA. Furthermore, this tool can be expanded to monitor other 
charged-small molecule-RNA interactions.  
In conclusion, to gain clinical success of drugs, it is important to understand the 
fundamental biochemistry behind their activity. These factors contribute to the 
improvement of existing drugs and also to the rational design of new drugs with few 
drawbacks. During the search for new anticancer drug candidates, biological ligands such 
as carbohydrates have received more attention. This thesis work provides evidence for 
carbohydrate-linked Pt(II) derivatives to act as promising anticancer drug candidates with 
tunable steric, electronic, and/or H-bonding properties for nucleic acid binding. 




comparable structural effects and potency (in DU145 cancer cells) as cisplatin, also with 
selectivity towards cancer cells. Overall, this study provided new perspectives for a future 
design of carbohydrate-linked platinum(II) antitumor compounds.  
Techniques and tools to understand how existing drugs work are likely to 
influence drug development to a similar extent as the development process of new drugs. 
This thesis work also demonstrated cisplatin’s ability to act as an electrostatic probe in 
giving information about other cationic drug binding to RNA. It was successfully shown 
to predict the aminoglycoside binding to RNA based on the changes in the cisplatin 
reaction rates that are sensitive to the cationic molecules in the environment. It could be 
used to evaluate environmental and other factors that influence the drug-target 
interactions and therefore likely to shape future drug development. 
7.2 Future directions 
7.2.1 Evaluate the reactivity of compound 5 with thiol-containing molecules 
 
 One of the mechanisms for cancers to develop resistance towards Pt-based drugs 
is through deactivating the compounds by binding with thiol-containing molecules in the 
cell (e.g., glutathione, sulfur-containing peptides, and proteins).
59
 The slower reaction 
kinetics of 5 suggested that it could have limited off-target binding, which could be 
advantageous for avoiding drug resistance. To evaluate the binding kinetics of 5 with a 
sulfur-containing ligand, an HPLC-based kinetic study could be carried out with 
glutathione. Furthermore, a competition assay with guanosine or deoxyguanosine 
nucleosides with glutathione by using the same method could be used to compare the 





7.2.2 Characterize the adducts of compound 5 
 Multiple products were observed for compound 5 reaction with G and dG 
nucleosides. In rRNA probing experiments, compound 5 coordinating to G and A 
residues were observed. In this thesis work, only the adducts with G and dG nucleosides 
were identified by mass spectrometry. However, the coordination site of compound 5 on 
the nucleobases was not identified in this work. This can be done by using 
1
H-NMR 
analysis of 5-purine nucleobase adducts. Furthermore, computational modeling and 
energy calculations can be used to identify the reactivity preferences of 5 and understand 
the roles of the carbohydrate ligand. 
7.2.3 Translation inhibition assay  
Ribosome probing data showed compound 5 binding at functionally important 
regions of the ribosome. Furthermore, some binding sites were overlapping with well-
known drug binding sites. Therefore, the next step would be to analyze the effects of 
binding on the protein translation process. There are commercial in vitro protein 
translation kits that could be easily used to obtain such information. For example, the 
translation level of a marker protein (e.g., green fluorescence protein) could be measured 
to evaluate the ribosome function upon treatment with compound 5. Cisplatin treated 
ribosomes could be used as a positive control in such an experiment.   
7.2.4 Study cellular uptake mechanism of compound 5 
Cellular assays in this study showed higher potency and compound 5 
accumulations in GLUT-overexpressing cancer cells compared to normal cells. To 
confirm the GLUT-dependent compound 5 uptake, a competition study could be carried 




used to quantify the Pt accumulation levels by using ICP-MS. The cells could be treated 
with compound 5 in the presence and absence of the competitor (glucose), and the in vivo 
Pt level then quantified. Furthermore, to confirm the transporter as GLUT1, the MTT 























































































































































Figure B1. Representative results for the reactions of bis-activated Pt(II) complexes 
with DNA, RNA. Plots and gels for the reactions of bis-activated Pt(II) complexes with 
(a) DNA and (b) RNA are shown. The fraction of unreacted nucleic acid over time 
showed an exponential decay. ([DNA or RNA] = 0.7 μM, [Pt(II)] = 94 μM; 10 mM 







Figure B2. Representative results for the salt-dependent kinetic experiment of 
mono-activated Pt(II) complexes with DNA, RNA. Plots and gels for the reactions of 
bis-activated Pt(II) complexes with (a) DNA and (b) RNA are shown. The fraction of 
unreacted nucleic acid over time showed an exponential decay. The experiments were 
carried out with lower Na
+
 concentration with [DNA or RNA] = 0.7 μM, [Pt(II)] = 94 
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With the discovery of cisplatin in the 1960s, it has been widely studied as a 
precursor for anticancer drug development. Despite its effectiveness against certain 
cancers, clinical usage of cisplatin is restricted by a number of side effects and resistance. 
In the past decade, scientists have been exploring biologically important ligands such as 
sugar derivatives in the hope of overcoming such challenges. Attachment of a sugar 
moiety could facilitate lower accumulation of platinum drugs in the body as well as 
enhance cellular uptake. In this study, a carbohydrate-linked cisplatin analog, cis-
dichlorido[(2-β-D-glucopyranosidyl)propane-1,3-diammine]platinum (5) has been 
studied. The aim was to evaluate the impact of the carbohydrate moiety on the reaction 
kinetics with nucleosides, target site identification, structural impacts on 
oligonucleotides, and selective cancer cell targeting. All of the experiments in this thesis 
work were carried out in comparison to the parent compound cisplatin. Compound 5 was 
synthesized and a reactivity study was carried out with deoxy-/ribonucleosides and 
oligonucleotides using high performance liquid chromatography (HPLC) and liquid 




was carried out comparing 5 and cisplatin with DNA and RNA oligos, with mono- and 
bis-activated complexes. A salt dependence kinetic study was also carried out to 
understand the contribution of electrostatics on the reactivity. A study was done to 
analyze the effects of compound 5 on DNA duplex structure by measuring the bending 
angles. Furthermore, probing studies on ribosomal RNA (rRNA) showed compound 5 
localization on rRNA. The potency of the compound was assessed by MTT assays. 
Overall, mono-activated compound 5 showed preferred binding to G over dG, which is 
opposite of the preference of cisplatin for dG. A similar trend was observed for mono-
activated 5 at the oligonucleotide level, in which RNA binding was preferred over DNA. 
However, in all the experiments, the reaction rate for mono- or bis-activated 5 was lower 
(≥2.5-fold) than that of aquated cisplatin. Data from the kinetic experiments suggest that 
the bulky carbohydrate ligand may play a role in reducing the reactivity of compound 5. 
Salt dependence kinetic data suggested the RNA binding preference of 5 may come from 
its ability to form additional hydrogen-bonding interactions with the target compared to 
cisplatin. Therefore, glycoconjugation alters target specificity of the platinum compound. 
Furthermore, compound 5 formed platinum adducts that bend the DNA structure in a 
manner similar to cisplatin. Cell-based assays showed that 5 has selectivity towards 
glucose transporter (GLUT) overexpressing cancer cells (DU145) over normal cells 
(RWPE1). Overall, these findings support the potential of using glycoconjugated 
platinum complexes as lead compounds for anticancer drug development with controlled 
activity and target selectivity.   
Electrostatics play an important role in RNA-ligand interactions. Positively 




Monovalent and divalent ions affect the electrostatic properties and influence these 
interactions; however, few methods exist to study these interactions in solution. This 
work focused on the use of cationic transition metal complexes as tools to study the 
electrostatic contributions of drug-RNA interactions. More specifically, positively 
charged mono-activated cisplatin and small model rRNA constructs were employed. The 
rates of the platination were determined by using gel shift analysis in the presence of 
different aminoglycosides. The rates of platination with RNA were shown to decrease in 
the presence of aminoglycosides, suggesting a competition between cisplatin and 
aminoglycosides to bind to the RNA. This work demonstrated the utility of monoaquated 
cisplatin kinetics as a tool to study RNA-aminoglycoside interactions. Overall, these 
findings are important for providing details on drug-RNA interactions, improving 
cationic drugs for nucleic acids, identifying unique RNA drug targets, and developing 
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